

METHOD FOR SCREENING CANCER

Field of the Invention

[0001] The present invention relates to method III for screening cancer.

5

Background of the Invention

[0002] Cervical cancer is one of the primary causes of death for women worldwide and in Taiwan. According to the statistics by the World Health Organization (WHO) in 2002, cervical cancer is the second cause of death for women cancers worldwide, only subsequent
10 to breast cancer. Periodic cervical cancer screening is the best way of cervical cancer prevention. Currently, there are two methods for cervical cancer screening. One is the most commonly known Pap smear and the other is HPV testing. Pap smear is performed by obtaining the discharge from the cervical, and observing whether cancerous lesion occurs in the detached epithelial cells by microscopy for early-stage detection of cervical cancer. HPV
15 testing is performed by using polymerase chain reaction (RT-PCR) or Hybrid Capture to examine whether human papilloma virus (HPV) is present in the sample.

[0003] However, because it requires physicians to obtain the sample and medical technologists/pathologists to interpret the data from of smear, in addition to high false negative rate and the subsequent delay in diagnosis and treatment of the precancerous lesion,
20 the required quality in human resource and cost is overly high. For many developing countries, it is difficult to promote. On the other hand, although HPV testing is highly sensitive, it is also prone to high false positive rate. Not only the patient worries in vain, but also much medical resource wasted in the follow-up examinations of these false positive patients. Therefore, there remains a problem of how to elevate the accuracy and convenience
25 of screening methods of cervical cancer for promoting cervical cancer screening.

[0004] Genomic deletions are considered an important factor in tumor formation. For a long time, we are used to the concept that the code of genes relies on the permutation and combination of the four bases. Early as in 1975, Knudson proposed the two-hit theory, pointing out that some mutations or deletions accompanying homologous tumor suppressor
30 genes may cause or are prone to cause cancer. However, other information that affects phenotype may exist in the modified base, 5-methylcytosine. 5-methylcytosine is found to exist in the palindrome sequence 5'-CpG-3' in mammalian cells. In mammalian cells, besides the regions that are called "CpG islands (CGIs)," most CpG dinucleotide pairs are methylated.

CpG islands refer to regions having about 1000 base pairs (1Kb) that contain large amounts of GC- and CpG-. Usually, they are present around the genes, and are found near the promoters of broadly-expressed genes. Methylation of cytosine occurs after DNA synthesis, which transfers methyl group from the methyl group donor, S-adenosylmethionine (SAM), to the 5th carbon of cytosine. This enzymatic reaction is carried out by DNA methyltransferase (DNMTs). DNMT1 is the primary methyltransferase in mammals, which is responsible for the post-replicative restoration of hemi-methylated positions to full methylation, and thus maintenance of methylation. On the other hand, DNMT3A and DNMT3B are considered to be responsible for methylation of new positions, a process called de novo methylation.

[0005] Loss of methylation in CpG dinucleotide pairs refers to the generally-known low degree of methylation which is the first epigenetic abnormality in cancer cells. However, researches in past few years indicate that site-specific hypermethylation (such as in some tumor suppressor genes) is associated with loss of function. This may provide selective advantages during tumor formation. Hypermethylation of CpG islands in the promoter region may induce chromatin remodeling through gene silencing accompanied with histone modification. In addition to chromosome deletion and gene mutation, epigenetic silencing of tumor suppressor genes caused by hypermethylation of promoter is also common in human cancers.

[0006] Recent researches in epidemiology demonstrate that the concentration of serum folate (a primary source of methyl group) is associated with the infection and clearance of HPV. In the metabolism of methyl cycle, genetic polymorphisms of enzymes are also reported as associated with the development of cervical epithelial lesions. Like the concept of super gene evolution, researches on the association between DNA methylation and cervical cancer are also prevailing. Researches on DNA methylation of cervical cancer increase with time, indicating the possibility of using methylation for cervical cancer screening. Due to the interaction between genetics and the environment, the degree of methylation of tumor suppressor genes varies among different genes and different populations. Different diseases may have different methylator phenotypes. However, the methylator phenotype of cervical cancer and association with HPV are still unknown. What specific genes would be methylated in cervical cancer and how many genes is required to meet the need in clinical application remain the issues that need to be verified in the future.

[0007] Based on the above, the current methods of cervical cancer screening still have many defects and are not properly designed. An improvement is needed.

[0008] The inventors of the subject application have filed relevant patent applications in Taiwan (TW Pat. Pub. No. 200831900, TW Pat. Pyb. No. 201038739), China (CN Appl. No. 200810094659.2, CN Appl. No. 200910135501.X), Malaysia (UI20085354) and the USA (US Pat. Pub. No. 20080311570, US Pat. Pub. No. 20110045465) (hereafter refers to as the prior applications). The method III for screening cancer is an extension of the prior applications. The inventors of the subject application discovered novel biomarkers for cancer screening and the screening methods.

Summary of the Invention

[0009] The purpose of present invention is to provide a method for screening cervical cancer for use as a first-line cervical cancer screen.

[0010] Another purpose of present invention is to provide a method for screening cervical cancer. The method not only can be used as a first-line cervical cancer screen but also can be used as a second-line cervical cancer screen to facilitate HPV testing or uncertain smear results so as to achieve more accurate cervical cancer screening results.

[0011] Still another purpose of present invention is to provide a method for screening cancer. In addition to applying to cervical cancer screening, the method can be used in the screening of other cancers (such as: ovarian cancer, liver cancer, colon cancer, breast cancer, oral cancer, endometrial cancer and sarcoma) to facilitate the determination on abnormal specimen.

[0012] A method of cancer screening to achieve the above purposes of the present invention is to detect the methylation status of target gene in the cells of a specimen to be detected. The detection serves as a screening indicator of the presence or absence of cancer. The method comprises the following steps:

[0013] step 1: providing the specimen to be detected;

[0014] step 2: detecting the methylation status of CpG sequence of at least one target gene which is at least one of ADRA1D, AJAP1, HS3ST2, MAGI2, POU4F2, POU4F3, PTGDR, SOX17 and SYT9 in genomic DNA of the specimen; and

[0015] step 3: determining whether cancer or precancerous lesions are present in the specimen according to the methylation status of the target gene, or utilizing the methylation status as an indicator of prognosis after treatment.

[0016] The specimen to be detected is Pap smear, ovarian cancer tissues, ascites, blood, urine, feces, phlegm, oral mucosal cells, gastric fluid, bile, cervical epithelial cells, or cancer tissues after surgery.

[0017] The method of detecting the methylation status of CpG sequence of target gene comprises, but is not limited to, methylation specific polymerase chain reaction (MSP), quantitative methylation specific polymerase chain reaction (QMSP), bisulfite sequencing (BS), microarrays, mass spectrometry, denaturing high performance liquid chromatography (DHPLC).

[0018] The target gene ADRA1D has the nucleotide sequence as set forth in SEQ ID NO: 1.

[0019] The target gene AJAP1 has the nucleotide sequence as set forth in SEQ ID NO: 2.

[0020] The target gene HS3ST2 has the nucleotide sequence as set forth in SEQ ID NO: 3.

[0021] The target gene MAGI2 has the nucleotide sequence as set forth in SEQ ID NO: 4.

[0022] The target gene POU4F2 has the nucleotide sequence as set forth in SEQ ID NO: 5.

[0023] The target gene POU4F3 has the nucleotide sequence as set forth in SEQ ID NO: 6.

[0024] The target gene PTGDR has the nucleotide sequence as set forth in SEQ ID NO: 7.

[0025] The target gene SOX17 has the nucleotide sequence as set forth in SEQ ID NO: 8.

[0026] The target gene SYT9 has the nucleotide sequence as set forth in SEQ ID NO: 9.

[0027] The methylation status of the target gene ADRA1D is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 10-11.

[0028] The methylation status of the target gene AJAP1 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 12-13.

[0029] The methylation status of the target gene HS3ST2 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 14-15.

[0030] The methylation status of the target gene MAGI2 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 16-17.

[0031] The methylation status of the target gene POU4F2 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 18-19.

[0032] The methylation status of the target gene POU4F3 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 20-21.

[0033] The methylation status of the target gene PTGDR is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 22-23.

[0034] The methylation status of the target gene SOX17 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 24-25.

5 **[0035]** The methylation status of the target gene SYT9 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 26-27.

[0036] The primers comprise sequences having at least 80% sequence identity, complementarity or at least 10 contiguous nucleotides identical to the corresponding sequences.

10 **[0037]** In addition, the above screening markers and screening method can further be used in the screening of cervical cancer, ovarian cancer, liver cancer, colon cancer, breast cancer, oral cancer, endometrial cancer or sarcoma.

[0038] The term "specimen to be detected" refers to an in vitro sample to be detected. The sample includes the in vitro specimen sample of the above-mentioned Pap smear, ascites,
15 blood, urine, feces, phlegm, oral mucosal cells, gastric fluid, bile, cervical epithelial cells, or cancer tissues after surgery. The cancer screening method of the present invention is used to detect the methylation status of target genes in the in vitro samples, and may serve as a screen indicator for various cancers. The cancer screening method and screening markers provided by the present invention can be used by screening researchers to perform screening in the
20 laboratory.

[0039] The term "indicator gene" refers to the target gene in which CpG sequences are methylated. The methylation status of the target gene in the specimen cells to be detected is detected and used as a screening indicator of the presence or absence cancer.

[0040] The method of screening cancer provided by the present invention has the
25 following advantages compared to the above-mentioned prior techniques:

[0041] 1. The method of screening cancer provided by the present invention uses the degree of methylation of specific genes in the in vitro specimen as the screening indicator for the presence or absence of cancer. Compared to Pap smear or HPV testing, the sensitivity and specificity of the method of screening cancer of the present invention are both higher.

30 **[0042]** 2. The method of screening cancer provided by the present invention, in addition to being applied on cervical cancer detection, can also be used in the screening of other cancers (such as: ovarian cancer, liver cancer, colon cancer, breast cancer, oral cancer, endometrial cancer and sarcoma) to facilitate the determination on abnormal specimen.

Brief Description of the Drawings

[0043] Figure 1 shows the result of degree of methylation of the target gene ADRA1D used in the method of screening cancer of the present invention by bisulfite sequencing (BS) in various normal and cancerous tissue samples: (A) uterine cervix, (B) ovarian tumor, (C) liver, (D) colon, (E) breast, and (F) oral tissue.

[0044] Figure 2 shows the result of degree of methylation of the target gene AJAP1 used in the method of screening cancer of the present invention by bisulfite sequencing (BS) in various normal and cancerous tissue samples: (A) uterine cervix, (B) ovarian tumor, (C) colon, (D) breast, (E) oral tissue, and (F) endometrial tissue.

[0045] Figure 3 shows the result of degree of methylation of the target gene HS3ST2 used in the method of screening cancer of the present invention by bisulfite sequencing (BS) in various normal and cancerous tissue samples: (A) uterine cervix, (B) ovarian tumor, (C) colon, (D) breast, (E) oral tissue, and (F) endometrial tissue.

[0046] Figure 4 shows the result of degree of methylation of the target gene MAGI2 used in the method of screening cancer of the present invention by bisulfite sequencing (BS) in various normal and cancerous tissue samples: (A) uterine cervix, (B) ovarian tumor, (C) colon, (D) breast, (E) oral tissue, (F) endometrial tissue, and (G) sarcoma.

[0047] Figure 5 shows the result of degree of methylation of the target gene POU4F2 used in the method of screening cancer of the present invention by bisulfite sequencing (BS) in various normal and cancerous tissue samples: (A) uterine cervix, (B) ovarian tumor, (C) liver, (D) colon, (E) breast, (F) oral tissue, and (G) endometrial tissue.

[0048] Figure 6 shows the result of degree of methylation of the target gene POU4F3 used in the method of screening cancer of the present invention by bisulfite sequencing (BS) in various normal and cancerous tissue samples: (A) uterine cervix, (B) ovarian tumor, (C) colon, (D) breast, (E) endometrial tissue, and (F) sarcoma.

[0049] Figure 7 shows the result of degree of methylation of the target gene PTGDR used in the method of screening cancer of the present invention by bisulfite sequencing (BS) in various normal and cancerous tissue samples: (A) uterine cervix, (B) ovarian tumor, (C) liver, (D) breast, (E) oral tissue, and (F) endometrial tissue.

[0050] Figure 8 shows the result of degree of methylation of the target gene PTGDR used in the method of screening cancer of the present invention by bisulfite sequencing (BS) in

various normal and cancerous tissue samples: (A) uterine cervix, (B) liver, (C) colon, and (D) breast.

[0051] Figure 9 shows the result of degree of methylation of the target gene SYT9 used in the method of screening cancer of the present invention by bisulfite sequencing (BS) in various normal and cancerous tissue samples: (A) uterine cervix, (B) liver, (C) colon, (D) breast, (E) oral tissue, and (F) endometrial tissue.

Detailed Description of the Invention

[0052] The present invention will be further illustrated by the following examples. However, the examples are only for illustrative purpose and should not be construed as any limitation to the present invention.

Example 1: Materials and methods

1. Materials

[0053] The tested materials comprise a series of intact cervical lesion samples, including: squamous cell carcinoma (SCC), adenocarcinoma (AC), and normal cervical samples. All the cervical samples (SCC + AC, n=20; normal, n=20), ovary samples (cancer of ovary, n=19; normal, n=14), colon samples (Ca of colon, n=18; normal, n=18), liver tissue samples (HCC, n=18; normal, n=18), oral samples (oral Ca, n=20; normal, n=19), endometrial cancer samples (endometrial Ca, n=20; normal, n=20), breast tissue samples (cancer of breast, n=17; normal, n=17), sarcoma samples (sarcoma, n=18; normal, n=16) are obtained from Tri-Service General Hospital in Taipei. The genomic DNA of each sample is extracted using QIAamp DNA kit followed by DNA modification kit (CpGenome™ DNA Modification Kit, Millipore, Temecula, CA) produced by Millipore to perform bisulfite modification for analysis of DNA methylation of the whole genome.

2. Analysis of DNA methylation using whole genomic methylation chip (Illumina Infinium HumanMethylation27 BeadChip)

[0054] Extract DNA from cancer tissue samples and normal tissue samples, respectively. Subject the extracted DNA to bisulfite modification and then adjust the products to an equal concentration (ng/μl). Mix the cancer tissue sample DNA or normal tissue sample DNA having the same concentration into two samples for detection, and analyze the degree of methylation of the whole genome on Infinium HumanMethylation27 methylation chip (Illumina, San Diego, CA). The experimental steps are performed according to the

manufacturer's instructions. Analyze the degree of methylation of genes on each chip using Illumina chip scanner (Bead Array reader) and GenomeStudio software (Illumina).

[0055] Infinium HumanMethylation27 methylation chip contains 14,475 genes and can detect the degree of methylation on 27,578 CpG sites in these genes. The analysis of degree of methylation on CpG sites is presented by "β values." The β value of each CpG site is between 0 and 1, where 0 represents no methylation and 1 represents 100% methylation.

3. Bisulfite modification, quantitative methylation-specific PCR (qMSP), and pyrosequencing

[0056] Use the DNA modification kit (CpGenome™ DNA Modification Kit, Millipore, Temecula, CA) produced by Millipore to perform bisulfite modification: obtain 1 μg sample genomic DNA and perform chemical modification to the genomic DNA using sodium bisulfite. In single chain DNA, all non-methylated cytosine will undergo deamination and be converted into uracil. Methylated cytosine will not be modified and will maintain the status of 5-methylcytosine. Finally, dissolve the sample DNA after reaction into 70μl, 55°C TE buffer for methylation specific quantitative PCR.

[0057] Use the normal DNA of human peripheral blood for bisulfite modification and use the same as a control group that contains non-methylated promoter sequence.

[0058] Use qMSP primers and probes to perform methylation specific quantitative PCR analysis on 1 μg sample genomic DNA that has been modified by bisulfite and control DNA. The qMSP primers and probes specifically recognize methylated gene sequence. The sequences of the qMSP primers and probes for each target gene are shown in Table 1. The total volume of methylation specific quantitative PCR product is 20μl comprising 1 μl modified template DNA, 250 nM of each primer, 225 nM of fluorescence probe and 2X FastStart Universal Probe Master (Rox) (Roche). The mixed reactants are placed in ABI 7900HT Fast Real-Time PCR System. The initial denature is performed at 95°C for 10 minutes followed by denature at 95°C for 15 seconds, annealing at 60°C and synthesis for 1 minute as a cycle. The denature, annealing and synthesis steps are repeated for 45 cycles. Methylation quantitative data analysis is performed using SDS 2.3 software, setting the threshold =0.128 and the baseline between 3 to 15. Based on the methylation Index (Meth-Index) formula: $[100,00 \times 2]^{[(\text{COL2A of Ct}) - (\text{Gene of Ct})]}$, subject the internal control gene COL2A and the quantitative data of methylation specific genes to calculation for the degree of methylation of target genes in the samples.

Table 1 Sequences of MSP primers used in Methylation Specific PCR

Gene Name	Species of primers/probes	Sequences of primers/probes		
ADRA1D	M	Positive strand(F')	5' ggtaggtagtttcgttttcggatagtc 3'	SEQ ID No: 10
		Negative strand(R')	5' aaacacaaaacgaacgaccgaca 3'	SEQ ID No: 11
AJAP1	M	Positive strand(F')	5' ttgtagagtttttcgattcggtagc 3'	SEQ ID No: 12
		Negative strand(R')	5' accgaaactccgcgccgataa 3'	SEQ ID No: 13
HS3ST2	M	Positive strand(F')	5' gtaagagtttgggagcgttcgagtc 3'	SEQ ID No: 14
		Negative strand(R')	5' caaaaaatcccgaacaacgac 3'	SEQ ID No: 15
MAGI2	M	Positive strand(F')	5' cgtagagttcgagatgtggtattaggc 3'	SEQ ID No: 16
		Negative strand(R')	5' aaactcctatacgaacgacgcta 3'	SEQ ID No: 17
POU4F2	M	Positive strand(F')	5' tactccccctcaaaactaaatccttc 3'	SEQ ID No: 18
		Negative strand(R')	5' gcgggacgttgcaag 3'	SEQ ID No: 19
POU4F3	M	Positive strand(F')	5' agcgcgggcgttgagtagc 3'	SEQ ID No: 20
		Negative strand(R')	5' cgcgtcctaacaaaataacaacgaa 3'	SEQ ID No: 21
PTGDR	M	Positive strand(F')	5' ttgttcgcgtttttaatgttagc 3'	SEQ ID No: 22
		Negative strand(R')	5' aaaaaaactccgaaaacgacgaaat 3'	SEQ ID No: 23
SOX17*	M	Positive strand(F')	5' ggagattcgcgtagttttcg 3'	SEQ ID No: 24
		Negative strand(R')	5' aacccgaccatcaccgcg 3'	SEQ ID No: 25
SYT9	M	Positive strand(F')	5' tggggtcgtcgttattttatttgc 3'	SEQ ID No: 26
		Negative strand(R')	5' ccgcccgatccctccgcg 3'	SEQ ID No: 27

Primer species M represents the MSP primer that can specifically recognize methylated gene sequences

[0059] The purpose of using pyrosequencing to analyze the fragment of target gene is to accurately quantify the percentage of degree of methylation on CpG sites of the target genes.

- 5 Before performing pyrosequencing, the software PyroMark Assay Design 2.0 (QIAGEN) should be used to design the primers for biotin marker. Use PCR amplification to cover the gene fragment of target gene CpG sites followed by pyrosequencing to detect the percentage of methylation on CpG sites of the target genes. First of all, add the Pap smear cell or tissue

sample DNA that has been modified by bisulfite to the primer pairs containing biotin label and the PCR reaction solution of PyroMark PCR kit (QIAGEN). After PCR amplification of target fragment, check whether the PCR amplified fragment is correct with 2.0 % agar gel. Perform purification and denature of the DNA sample using PyroMark Q24 Vacuum Workstation (QIAGEN). After addition of sequencing primers, perform pyrosequencing and methylation analysis using PyroMark Q24 System (QIAGEN).

Example 2: Screening of methylated target genes

[0060] Screen 14,475 genes using Infinium HumanMethylation27K methylation chips.

[0061] (1) Select those having higher methylation rate score (β value >0.4 and <0.4), combine Gene Expression database (GE07803), and analyze gene enrichment (The Database for Annotation, Visualization and Integrated Discovery, DAVID). 92 genes are selected;

[0062] (2) Cancer cell lines are treated with 5-AZc and TSA. Analyze the 92 genes using QRT-PCR to confirm that gene expression is influenced by methylation. 61 genes are left;

[0063] (3) Mix the samples to be detected and use MSP to analyze DNA methylation of the 61 genes. 26 genes are left;

[0064] (4) Analyze DNA methylation in cancer samples for the 26 genes by MSP. 21 genes are left;

[0065] (5) Analyze DNA methylation in cancer tissues for the 21 genes by MSP. 16 genes are left;

[0066] (6) Analyze DNA methylation in cancer samples for the 16 genes by Q-MSP. 14 genes are left.

[0067] Confirm the methylation status of genes by pyrosequencing. The selected final nine target genes may be highly methylated in cancer cells. The genes are: ADRA1D (SEQ ID No: 1), AJAP1 (SEQ ID No: 2), HS3ST2 (SEQ ID No: 3), MAGI2 (SEQ ID No:4), POU4F2 (SEQ ID No:5), POU4F3 (SEQ ID No:6), PTGDR (SEQ ID No:7), SOX17 (SEQ ID No:8) and SYT9 (SEQ ID No: 9). The detailed information is shown in Table 3. From Table 3, it can be known that while HS3ST2 is known to be associated with colon cancer and breast cancer and POU4F2 and SOX17 are known to be associated with breast cancer and liver cancer, there are few researches that demonstrate the association between these genes and cervical cancer or other cancer.

Table 3 The detailed information of methylated genes selected with Infinium HumanMethylation27K methylation chip in cervical cancer or other cancers

Gene name	UniGene number	Location in chromosome	Gene full name	SEQ ID No
ADRA1D	NM_000678	20p13	alpha-1D-, receptor	SEQ ID No: 1
AJAP1	NM_018836	1p36.32	adherens junctions associated protein 1	SEQ ID No: 2
HS3ST2	NM_006043	16p12	heparan sulfate (glucosamine) 3-O-sulfotransferase 2	SEQ ID No: 3
MAGI2	NM_012301	7q21	membrane associated guanylate kinase, WW and PDZ domain containing 2	SEQ ID No: 4
POU4F2	NM_004575	4q31.2	POU class 4 homeobox 2	SEQ ID No: 5
POU4F3	NM_002700	5q32	POU class 4 homeobox 3	SEQ ID No: 6
PTGDR	NM_000953	14q22.1	prostaglandin D2 receptor	SEQ ID No: 7
SOX17	NM_022454	8q11.23	SRY (sex determining region Y)-box 17	SEQ ID No: 8
SYT9	NM_175733	11p15.4	synaptotagmin IX	SEQ ID No: 9

Example 3: Methylation analysis of target genes in cervical cancer samples

[0068] Use methylation specific PCR (MSP) to analyze the methylation status of the nine target genes in cervical squamous cell cancer samples. The results show the degree of methylation of ADRA1D, AJAP1, HS3ST2, MAGI2, POU4F2, POU4F3, PTGDR, SOX17 and SYT9 in normal cervical samples (SCC N) (the medians are 0.34, 0.18, 0.19, 2.58, 7.62, 0.77, 0.16, 0.17 and 0.31, respectively); and the degree of methylation of ADRA1D, AJAP1, HS3ST2, MAGI2, POU4F2, POU4F3, PTGDR, SOX17 and SYT9 in cervical cancer samples (SCC T) (the medians are 911.37, 1558.97, 1088.65, 713.92, 535.01, 1552.71, 305.84, 248.29 and 551.84, respectively). After Mann-Whitney test, the two groups of data reach $P < 0.0001$ among each group. The difference is statistically significant. The above are as shown in Figure 1(A), Figure 2(A), Figure 3(A), Figure 4(A), Figure 5(A), Figure 6(A), Figure 7(A), Figure 8(A), and Figure 9(A).

Example 4: Methylation analysis of target genes in ovarian tumor samples

[0069] Use methylation specific PCR (MSP) to analyze the methylation status of the seven target genes in ovarian tumor samples. The results show the degree of methylation of ADRA1D, AJAP1, HS3ST2, MAGI2, POU4F2, POU4F3 and PTGDR in benign ovarian tumor samples (ovary N) (the medians are 4.25, 5.19, 0.00, 10.91, 2.06, 3.60 and 1.57, respectively); and the degree of methylation of ADRA1D, AJAP1, HS3ST2, MAGI2, POU4F2, POU4F3 and PTGDR in malignant ovarian tumor samples (ovary T) (the medians are 13.62, 10.76, 114.38, 33.08, 4.28, 21.97 and 28.40, respectively). After Mann-Whitney test, the two groups of data reach $P < 0.05$ among each group. The difference is statistically significant. The above are as shown in Figure 1(B), Figure 2(B), Figure 3(B), Figure 4(B), Figure 5(B), Figure 6(B), and Figure 7(B).

Example 5: Methylation analysis of target genes in liver cancer samples

[0070] Use methylation specific PCR (MSP) to analyze the methylation status of the five target genes in liver cancer samples. The results show the degree of methylation of ADRA1D, POU4F2, PTGDR, SOX17 and SYT9 in normal liver tissue samples (HCC N) (the medians are 35.29, 6.25, 49.30, 20.15 and 19.70, respectively); and the degree of methylation of ADRA1D, POU4F2, PTGDR, SOX17 and SYT9 in liver cancer samples (HCC T) (the medians are 202.10, 53.73, 275.76, 111.25 and 154.65, respectively). After Mann-Whitney test, the two groups of data reach $P < 0.0001$ among each group. The difference is statistically significant. The above are as shown in Figure 1(C), Figure 5(C), Figure 7(C), Figure 8(B), and Figure 9(B).

Example 6: Methylation analysis of target genes in colon cancer samples

[0071] Use methylation specific PCR (MSP) to analyze the methylation status of the eight target genes in colon cancer samples. The results show the degree of methylation of ADRA1D, AJAP1, HS3ST2, MAGI2, POU4F2, POU4F3, SOX17 and SYT9 in normal colon tissue samples (colon N) (the medians are 59.21, 228.97, 292.95, 123.44, 591.64, 249.72, 80.12 and 52.63, respectively); and the degree of methylation of ADRA1D, AJAP1, HS3ST2, MAGI2, POU4F2, POU4F3, SOX17 and SYT9 in colon cancer samples (colon T) (the medians are 83.47, 2312.91, 2301.12, 799.41, 1615.48, 1058.53, 751.06 and 601.65, respectively). After Mann-Whitney test, the two groups of data reach $P < 0.05$ among each group. The difference is statistically significant. The above are as shown in Figure 1(D), Figure 2(C), Figure 3(C), Figure 4(C), Figure 5(D), Figure 6(C), Figure 8(C), and Figure 9(C).

Example 7: Methylation analysis of target genes in breast cancer samples

[0072] Use methylation specific PCR (MSP) to analyze the methylation status of the nine target genes in cervical squamous cell cancer samples. The results show the degree of methylation of ADRA1D, AJAP1, HS3ST2, MAGI2, POU4F2, POU4F3, PTGDR, SOX17 and SYT9 in normal breast tissue samples (breast Ca N) (the medians are 11.78, 22.28, 112.81, 24.55, 30.23, 31.29, 43.64, 12.02 and 5.53, respectively); and the degree of methylation of ADRA1D, AJAP1, HS3ST2, MAGI2, POU4F2, POU4F3, PTGDR, SOX17 and SYT9 in breast cancer samples (breast Ca T) (the medians are 57.19, 260.96, 281.64, 193.70, 77.06, 310.34, 341.97, 77.05 and 25.24, respectively). After Mann-Whitney test, the two groups of data reach $P < 0.01$ among each group. The difference is statistically significant. The above are as shown in Figure 1(E), Figure 2(D), Figure 3(D), Figure 4(D), Figure 5(E), Figure 6(D), Figure 7(D), Figure 8(D), and Figure 9(D).

Example 8: Methylation analysis of target genes in oral cancer samples

[0073] Use methylation specific PCR (MSP) to analyze the methylation status of the seven target genes in oral cancer samples. The results show the degree of methylation of ADRA1D, AJAP1, HS3ST2, MAGI2, POU4F2, PTGDR and SYT9 in normal oral tissue samples (oral Ca N) (the medians are 10.25, 0.0065, 115.98, 0.00, 30.23, 10.47 and 0.00, respectively); and the degree of methylation of ADRA1D, AJAP1, HS3ST2, MAGI2, POU4F2, PTGDR and SYT9 in oral cancer samples (oral Ca T) (the medians are 26.44, 0.0107, 381.49, 54.59, 77.06, 32.78 and 10.85, respectively). After Mann-Whitney test, the two groups of data reach $P < 0.05$ among each group. The difference is statistically significant. The above are as shown in Figure 1(F), Figure 2(E), Figure 3(E), Figure 4(E), Figure 5(F), Figure 7(E), and Figure 9(E).

Example 9: Methylation analysis of target genes in endometrial cancer samples

[0074] Use methylation specific PCR (MSP) to analyze the methylation status of the seven target genes in endometrial cancer samples. The results show the degree of methylation of AJAP1, HS3ST2, MAGI2, POU4F2, POU4F3, PTGDR and SYT9 in normal endometrial tissue samples (Em N) (the medians are 0.00, 0.00, 0.00, 16.42, 0.31, 0.00 and 0.63, respectively); and the degree of methylation of AJAP1, HS3ST2, MAGI2, POU4F2, POU4F3, PTGDR and SYT9 in endometrial cancer samples (Em T) (the medians are 535.78,

1456.23, 504.15, 248.83, 89.86, 148.19 and 0.43, respectively). After Mann-Whitney test, the two groups of data reach $P < 0.05$ among each group. The difference is statistically significant. The above are as shown in Figure 2(F), Figure 3(F), Figure 4(F), Figure 5(G), Figure 6(E), Figure 7(F), and Figure 9(F).

5

Example 10: Methylation analysis of target genes in sarcoma samples

[0075] Use methylation specific PCR (MSP) to analyze the methylation status of the two target genes in sarcoma samples. The results show the degree of methylation of MAGI2 and POU4F3 in benign sarcoma samples (sar N) (the medians are 0.00 and 0.31, respectively);
10 and the degree of methylation of MAGI2 and POU4F3 in malignant sarcoma samples (sar T) (the medians are 5.20 and 89.86, respectively). After Mann-Whitney test, the two groups of data reach $P < 0.05$ among each group. The difference is statistically significant. The above are as shown in Figure 4(G) and Figure 6(F).

[0076] The above detailed descriptions are specific illustrations to the embodiments of
15 the present invention. However, the examples are not used to limit the patent scope of the present invention. The equivalent practice or alteration that do not deviate from the present invention such as alteration in the way to determine the degree of methylation of each target gene in the specimen to be detected and equivalent examples, should be covered in the patent scope.

20

Claims

What is claimed is:

1. A method III for screening cancer, which detects the methylation status of target gene in the cells of a specimen to be detected, and the detection serves as a screening
5 indicator of the presence or absence of cancer, characterized in that the method comprises the following steps:

step 1: providing the specimen to be detected;

step 2: detecting the methylation status of CpG sequence of at least one target gene which is at least one of ADRA1D, AJAP1, HS3ST2, MAGI2, POU4F2, POU4F3, PTGDR,
10 SOX17 and SYT9 in genomic DNA of the specimen; and

step 3: determining whether cancer or precancerous lesions are present in the specimen according to the methylation status of the target gene, or utilizing the methylation status as an indicator of prognosis after treatment.

2. The method III for screening cancer according to Claim 1, characterized in that the
15 specimen to be detected is Pap smear, ascites, blood, urine, feces, phlegm, oral mucosal cells, gastric fluid, bile, cervical epithelial cells, or an in vitro sample of cancer tissues after surgery.

3. The method III for screening cancer according to Claim 1, characterized in that the method of detecting the methylation status of CpG sequence of target gene is methylation
20 specific polymerase chain reaction, quantitative methylation specific polymerase chain reaction, bisulfite sequencing, microarray, mass spectrometry, denaturing high performance liquid chromatography, or pyrosequencing.

4. The method III for screening cancer according to Claim 1, characterized in that the target gene ADRA1D has the nucleotide sequence as set forth in SEQ ID NO: 1, the target gene AJAP1 has the nucleotide sequence as set forth in SEQ ID NO: 2, the target gene
25 HS3ST2 has the nucleotide sequence as set forth in SEQ ID NO: 3, the target gene MAGI2 has the nucleotide sequence as set forth in SEQ ID NO: 4, the target gene POU4F2 has the

nucleotide sequence as set forth in SEQ ID NO: 5, the target gene POU4F3 has the nucleotide sequence as set forth in SEQ ID NO: 6, the target gene PTGDR has the nucleotide sequence as set forth in SEQ ID NO: 7, the target gene SOX17 has the nucleotide sequence as set forth in SEQ ID NO: 8, the target gene SYT9 has the nucleotide sequence as set forth in SEQ ID NO: 9.

5 The method III for screening cancer according to Claim 1, characterized in that the methylation status of the target gene ADRA1D is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 10-11, the methylation status of the target gene AJAP1 is detected by the primer pairs having the nucleotide sequences as set forth in
 10 SEQ ID NO: 12-13, the methylation status of the target gene HS3ST2 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 14-15, the methylation status of the target gene MAGI2 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 16-17, the methylation status of the target gene POU4F2 is detected by the primer pairs having the nucleotide sequences as set forth in
 15 SEQ ID NO: 18-19, the methylation status of the target gene POU4F3 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 20-21, the methylation status of the target gene PTGDR is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 22-23, the methylation status of the target gene SOX17 is detected by the primer pairs having the nucleotide sequences as set forth in
 20 SEQ ID NO: 24-25, the methylation status of the target gene SYT9 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 26-27; the primers comprise sequences having at least 80% sequence identity, complementarity or at least 10 contiguous nucleotides identical to the corresponding sequences.

6. A method for screening cervical cancer, which detects the methylation status of
 25 target gene in the cells of a specimen to be detected, and the detection serves as a screening

indicator of the presence or absence of cervical cancer, characterized in that the method comprises the following steps:

step 1: providing the specimen to be detected;

step 2: detecting the methylation status of CpG sequence of at least one target gene

5 which is at least one of ADRA1D, AJAP1, HS3ST2, MAGI2, POU4F2, POU4F3, PTGDR, SOX17 and SYT9 in genomic DNA of the specimen; and

step 3: determining whether cervical cancer or pre-cervical cancer lesions are present in the specimen according to the methylation status of the target gene, or utilizing the methylation status as an indicator of prognosis after treatment.

10 7. The method for screening cervical cancer according to Claim 6, characterized in that the specimen to be detected is Pap smear, blood, urine, cervical epithelial cells, or an in vitro sample of cancer tissues after surgery.

8. The method for screening cervical cancer according to Claim 6, characterized in that the specimen to be detected is abnormal Pap smear.

15 9. The method for screening cervical cancer according to Claim 6, characterized in that the specimen to be detected is cervical cell specimen which is positive in human papilloma virus testing.

10. The method for screening cervical cancer according to Claim 6, characterized in that the method of detecting the methylation status of CpG sequence of target gene is
20 methylation specific polymerase chain reaction, quantitative methylation specific polymerase chain reaction, bisulfite sequencing, microarray, mass spectrometry, denaturing high performance liquid chromatography, or pyrosequencing.

11. The method for screening cervical cancer according to Claim 6, characterized in that the target gene ADRA1D has the nucleotide sequence as set forth in SEQ ID NO: 1, the
25 target gene AJAP1 has the nucleotide sequence as set forth in SEQ ID NO: 2, the target gene

HS3ST2 has the nucleotide sequence as set forth in SEQ ID NO: 3, the target gene MAGI2 has the nucleotide sequence as set forth in SEQ ID NO: 4, the target gene POU4F2 has the nucleotide sequence as set forth in SEQ ID NO: 5, the target gene POU4F3 has the nucleotide sequence as set forth in SEQ ID NO: 6, the target gene PTGDR has the nucleotide sequence as set forth in SEQ ID NO: 7, the target gene SOX17 has the nucleotide sequence as set forth in SEQ ID NO: 8, the target gene SYT9 has the nucleotide sequence as set forth in SEQ ID NO: 9.

12. The method for screening cervical cancer according to Claim 6, characterized in that the methylation status of the target gene ADRA1D is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 10-11, the methylation status of the target gene AJAP1 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 12-13, the methylation status of the target gene HS3ST2 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 14-15, the methylation status of the target gene MAGI2 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 16-17, the methylation status of the target gene POU4F2 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 18-19, the methylation status of the target gene POU4F3 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 20-21, the methylation status of the target gene PTGDR is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 22-23, the methylation status of the target gene SOX17 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 24-25, the methylation status of the target gene SYT9 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 26-27; the primers comprise sequences having at least 80% sequence identity, complementarity or at least 10 contiguous nucleotides identical to the corresponding sequences.

13. A method for screening ovarian cancer, which detects the methylation status of target gene in the cells of a specimen to be detected, and the detection serves as a screening indicator of the presence or absence of ovarian cancer, characterized in that the method comprises the following steps:

5 step 1: providing the specimen to be detected;

 step 2: detecting the methylation status of CpG sequence of at least one target gene which is at least one of ADRA1D, AJAP1, HS3ST2, MAGI2, POU4F2, POU4F3, PTGDR, SOX17 and SYT9 in genomic DNA of the specimen; and

 step 3: determining whether ovarian cancer is present in the specimen according to the
10 methylation status of the target gene, or utilizing the methylation status as an indicator of prognosis after treatment.

14. The method for screening ovarian cancer according to Claim 13, characterized in that the specimen to be detected is ovarian cancer tissue, ascites, blood, urine, or an in vitro sample of cancer tissues after surgery.

15 15. The method for screening ovarian cancer according to Claim 13, characterized in that the method of detecting the methylation status of CpG sequence of target gene is methylation specific polymerase chain reaction, quantitative methylation specific polymerase chain reaction, bisulfite sequencing, microarray, mass spectrometry, denaturing high performance liquid chromatography, or pyrosequencing.

20 16. The method for screening ovarian cancer according to Claim 13, characterized in that the target gene ADRA1D has the nucleotide sequence as set forth in SEQ ID NO: 1, the target gene AJAP1 has the nucleotide sequence as set forth in SEQ ID NO: 2, the target gene HS3ST2 has the nucleotide sequence as set forth in SEQ ID NO: 3, the target gene MAGI2 has the nucleotide sequence as set forth in SEQ ID NO: 4, the target gene POU4F2 has the
25 nucleotide sequence as set forth in SEQ ID NO: 5, the target gene POU4F3 has the nucleotide

sequence as set forth in SEQ ID NO: 6, the target gene PTGDR has the nucleotide sequence as set forth in SEQ ID NO: 7, the target gene SOX17 has the nucleotide sequence as set forth in SEQ ID NO: 8, the target gene SYT9 has the nucleotide sequence as set forth in SEQ ID NO: 9.

5 17. The method for screening ovarian cancer according to Claim 13, characterized in that the methylation status of the target gene ADRA1D is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 10-11, the methylation status of the target gene AJAP1 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 12-13, the methylation status of the target gene HS3ST2 is detected by
10 the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 14-15, the methylation status of the target gene MAGI2 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 16-17, the methylation status of the target gene POU4F2 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 18-19, the methylation status of the target gene POU4F3 is detected by the
15 primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 20-21, the methylation status of the target gene PTGDR is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 22-23, the methylation status of the target gene SOX17 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 24-25, the methylation status of the target gene SYT9 is detected by the primer
20 pairs having the nucleotide sequences as set forth in SEQ ID NO: 26-27; the primers comprise sequences having at least 80% sequence identity, complementarity or at least 10 contiguous nucleotides identical to the corresponding sequences.

18. A method for screening liver cancer, which detects the methylation status of target gene in the cells of a specimen to be detected, and the detection serves as a screening

indicator of the presence or absence of liver cancer, characterized in that the method comprises the following steps:

step 1: providing the specimen to be detected;

step 2: detecting the methylation status of CpG sequence of at least one target gene

5 which is at least one of ADRA1D, AJAP1, HS3ST2, MAGI2, POU4F2, POU4F3, PTGDR, SOX17 and SYT9 in genomic DNA of the specimen; and

step 3: determining whether liver cancer is present in the specimen according to the methylation status of the target gene, or utilizing the methylation status as an indicator of prognosis after treatment.

10 19. The method for screening liver cancer according to Claim 18, characterized in that the specimen to be detected is liver tissue, feces, gastric fluid, bile, ascites, blood, urine, or an in vitro sample of cancer tissues after surgery.

20. The method for screening liver cancer according to Claim 18, characterized in that the method of detecting the methylation status of CpG sequence of target gene is methylation
15 specific polymerase chain reaction, quantitative methylation specific polymerase chain reaction, bisulfite sequencing, microarray, mass spectrometry, denaturing high performance liquid chromatography, or pyrosequencing.

21. The method for screening liver cancer according to Claim 18, characterized in that the target gene ADRA1D has the nucleotide sequence as set forth in SEQ ID NO: 1, the
20 target gene AJAP1 has the nucleotide sequence as set forth in SEQ ID NO: 2, the target gene HS3ST2 has the nucleotide sequence as set forth in SEQ ID NO: 3, the target gene MAGI2 has the nucleotide sequence as set forth in SEQ ID NO: 4, the target gene POU4F2 has the nucleotide sequence as set forth in SEQ ID NO: 5, the target gene POU4F3 has the nucleotide sequence as set forth in SEQ ID NO: 6, the target gene PTGDR has the nucleotide sequence
25 as set forth in SEQ ID NO: 7, the target gene SOX17 has the nucleotide sequence as set forth

in SEQ ID NO: 8, the target gene SYT9 has the nucleotide sequence as set forth in SEQ ID NO: 9.

22. The method for screening liver cancer according to Claim 18, characterized in that the methylation status of the target gene ADRA1D is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 10-11, the methylation status of the target gene AJAP1 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 12-13, the methylation status of the target gene HS3ST2 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 14-15, the methylation status of the target gene MAGI2 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 16-17, the methylation status of the target gene POU4F2 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 18-19, the methylation status of the target gene POU4F3 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 20-21, the methylation status of the target gene PTGDR is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 22-23, the methylation status of the target gene SOX17 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 24-25, the methylation status of the target gene SYT9 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 26-27; the primers comprise sequences having at least 80% sequence identity, complementarity or at least 10 contiguous nucleotides identical to the corresponding sequences.

23. A method for screening colon cancer, which detects the methylation status of target gene in the cells of a specimen to be detected, and the detection serves as a screening indicator of the presence or absence of colon cancer, characterized in that the method comprises the following steps:

step 1: providing the specimen to be detected;

step 2: detecting the methylation status of CpG sequence of at least one target gene which is at least one of ADRA1D, AJAP1, HS3ST2, MAGI2, POU4F2, POU4F3, PTGDR, SOX17 and SYT9 in genomic DNA of the specimen; and

step 3: determining whether colon cancer or pre-colon cancer lesions are present in the specimen according to the methylation status of the target gene, or utilizing the methylation status as an indicator of prognosis after treatment.

24. The method for screening colon cancer according to Claim 23, characterized in that the specimen to be detected is colon tissue, ascites, blood, urine, feces, or an in vitro sample of cancer tissues after surgery.

25. The method for screening colon cancer according to Claim 23, characterized in that the method of detecting the methylation status of CpG sequence of target gene is methylation specific polymerase chain reaction, quantitative methylation specific polymerase chain reaction, bisulfite sequencing, microarray, mass spectrometry, denaturing high performance liquid chromatography, or pyrosequencing.

26. The method for screening colon cancer according to Claim 23, characterized in that the target gene ADRA1D has the nucleotide sequence as set forth in SEQ ID NO: 1, the target gene AJAP1 has the nucleotide sequence as set forth in SEQ ID NO: 2, the target gene HS3ST2 has the nucleotide sequence as set forth in SEQ ID NO: 3, the target gene MAGI2 has the nucleotide sequence as set forth in SEQ ID NO: 4, the target gene POU4F2 has the nucleotide sequence as set forth in SEQ ID NO: 5, the target gene POU4F3 has the nucleotide sequence as set forth in SEQ ID NO: 6, the target gene PTGDR has the nucleotide sequence as set forth in SEQ ID NO: 7, the target gene SOX17 has the nucleotide sequence as set forth in SEQ ID NO: 8, the target gene SYT9 has the nucleotide sequence as set forth in SEQ ID NO: 9.

27. The method for screening colon cancer according to Claim 23, characterized in that the methylation status of the target gene ADRA1D is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 10-11, the methylation status of the target gene AJAP1 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 12-13, the methylation status of the target gene HS3ST2 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 14-15, the methylation status of the target gene MAGI2 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 16-17, the methylation status of the target gene POU4F2 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 18-19, the methylation status of the target gene POU4F3 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 20-21, the methylation status of the target gene PTGDR is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 22-23, the methylation status of the target gene SOX17 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 24-25, the methylation status of the target gene SYT9 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 26-27; the primers comprise sequences having at least 80% sequence identity, complementarity or at least 10 contiguous nucleotides identical to the corresponding sequences.

28. A method for screening breast cancer, which detects the methylation status of target gene in the cells of a specimen to be detected, and the detection serves as a screening indicator of the presence or absence of breast cancer, characterized in that the method comprises the following steps:

step 1: providing the specimen to be detected;

step 2: detecting the methylation status of CpG sequence of at least one target gene which is at least one of ADRA1D, AJAP1, HS3ST2, MAGI2, POU4F2, POU4F3, PTGDR, SOX17 and SYT9 in genomic DNA of the specimen; and

step 3: determining whether breast cancer is present in the specimen according to the methylation status of the target gene, or utilizing the methylation status as an indicator of prognosis after treatment.

29. The method for screening breast cancer according to Claim 28, characterized in that the specimen to be detected is blood, urine, milk, secretions of the breast, cyst, puncture and biopsy specimen, or an in vitro sample of cancer tissues after surgery.

30. The method for screening breast cancer according to Claim 28, characterized in that the method of detecting the methylation status of CpG sequence of target gene is methylation specific polymerase chain reaction, quantitative methylation specific polymerase chain reaction, bisulfite sequencing, microarray, mass spectrometry, denaturing high performance liquid chromatography, or pyrosequencing.

31. The method for screening breast cancer according to Claim 28, characterized in that the target gene ADRA1D has the nucleotide sequence as set forth in SEQ ID NO: 1, the target gene AJAP1 has the nucleotide sequence as set forth in SEQ ID NO: 2, the target gene HS3ST2 has the nucleotide sequence as set forth in SEQ ID NO: 3, the target gene MAGI2 has the nucleotide sequence as set forth in SEQ ID NO: 4, the target gene POU4F2 has the nucleotide sequence as set forth in SEQ ID NO: 5, the target gene POU4F3 has the nucleotide sequence as set forth in SEQ ID NO: 6, the target gene PTGDR has the nucleotide sequence as set forth in SEQ ID NO: 7, the target gene SOX17 has the nucleotide sequence as set forth in SEQ ID NO: 8, the target gene SYT9 has the nucleotide sequence as set forth in SEQ ID NO: 9.

32. The method for screening breast cancer according to Claim 28, characterized in that the methylation status of the target gene ADRA1D is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 10-11, the methylation status of the target gene AJAP1 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 12-13, the methylation status of the target gene HS3ST2 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 14-15, the methylation status of the target gene MAGI2 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 16-17, the methylation status of the target gene POU4F2 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 18-19, the methylation status of the target gene POU4F3 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 20-21, the methylation status of the target gene PTGDR is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 22-23, the methylation status of the target gene SOX17 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 24-25, the methylation status of the target gene SYT9 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 26-27; the primers comprise sequences having at least 80% sequence identity, complementarity or at least 10 contiguous nucleotides identical to the corresponding sequences.

33. A method for screening oral cancer, which detects the methylation status of target gene in the cells of a specimen to be detected, and the detection serves as a screening indicator of the presence or absence of oral cancer, characterized in that the method comprises the following steps:

step 1: providing the specimen to be detected;

step 2: detecting the methylation status of CpG sequence of at least one target gene which is at least one of ADRA1D, AJAP1, HS3ST2, MAGI2, POU4F2, POU4F3, PTGDR, SOX17 and SYT9 in genomic DNA of the specimen; and

step 3: determining whether oral cancer or pre-oral cancer lesions are present in the specimen according to the methylation status of the target gene, or utilizing the methylation status as an indicator of prognosis after treatment.

34. The method for screening oral cancer according to Claim 33, characterized in that the specimen to be detected is blood, gargle cells, phlegm, oral mucosal cells, or an in vitro sample of cancer tissues after surgery.

35. The method for screening oral cancer according to Claim 33, characterized in that the method of detecting the methylation status of CpG sequence of target gene is methylation specific polymerase chain reaction, quantitative methylation specific polymerase chain reaction, bisulfite sequencing, microarray, mass spectrometry, denaturing high performance liquid chromatography, or pyrosequencing.

36. The method for screening oral cancer according to Claim 33, characterized in that the target gene ADRA1D has the nucleotide sequence as set forth in SEQ ID NO: 1, the target gene AJAP1 has the nucleotide sequence as set forth in SEQ ID NO: 2, the target gene HS3ST2 has the nucleotide sequence as set forth in SEQ ID NO: 3, the target gene MAGI2 has the nucleotide sequence as set forth in SEQ ID NO: 4, the target gene POU4F2 has the nucleotide sequence as set forth in SEQ ID NO: 5, the target gene POU4F3 has the nucleotide sequence as set forth in SEQ ID NO: 6, the target gene PTGDR has the nucleotide sequence as set forth in SEQ ID NO: 7, the target gene SOX17 has the nucleotide sequence as set forth in SEQ ID NO: 8, the target gene SYT9 has the nucleotide sequence as set forth in SEQ ID NO: 9.

37. The method for screening oral cancer according to Claim 33, characterized in that the methylation status of the target gene ADRA1D is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 10-11, the methylation status of the target gene AJAP1 is detected by the primer pairs having the nucleotide sequences as set forth in
5 SEQ ID NO: 12-13, the methylation status of the target gene HS3ST2 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 14-15, the methylation status of the target gene MAGI2 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 16-17, the methylation status of the target gene POU4F2 is detected by the primer pairs having the nucleotide sequences as set forth in
10 SEQ ID NO: 18-19, the methylation status of the target gene POU4F3 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 20-21, the methylation status of the target gene PTGDR is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 22-23, the methylation status of the target gene SOX17 is detected by the primer pairs having the nucleotide sequences as set forth in
15 SEQ ID NO: 24-25, the methylation status of the target gene SYT9 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 26-27; the primers comprise sequences having at least 80% sequence identity, complementarity or at least 10 contiguous nucleotides identical to the corresponding sequences.

38. A method for screening endometrial cancer, which detects the methylation status
20 of target gene in the cells of a specimen to be detected, and the detection serves as a screening indicator of the presence or absence of endometrial cancer, characterized in that the method comprises the following steps:

step 1: providing the specimen to be detected;

step 2: detecting the methylation status of CpG sequence of at least one target gene which is at least one of ADRA1D, AJAP1, HS3ST2, MAGI2, POU4F2, POU4F3, PTGDR, SOX17 and SYT9 in genomic DNA of the specimen; and

step 3: determining whether endometrial cancer is present in the specimen according to the methylation status of the target gene, or utilizing the methylation status as an indicator of prognosis after treatment.

39. The method for screening endometrial cancer according to Claim 38, characterized in that the specimen to be detected is blood, urine, vaginal-flushed substances, menses, tissues from dilatation and curettage of uterine, or an in vitro sample of cancer tissues after surgery.

40. The method for screening endometrial cancer according to Claim 38, characterized in that the method of detecting the methylation status of CpG sequence of target gene is methylation specific polymerase chain reaction, quantitative methylation specific polymerase chain reaction, bisulfite sequencing, microarray, mass spectrometry, denaturing high performance liquid chromatography, or pyrosequencing.

41. The method for screening endometrial cancer according to Claim 38, characterized in that the target gene ADRA1D has the nucleotide sequence as set forth in SEQ ID NO: 1, the target gene AJAP1 has the nucleotide sequence as set forth in SEQ ID NO: 2, the target gene HS3ST2 has the nucleotide sequence as set forth in SEQ ID NO: 3, the target gene MAGI2 has the nucleotide sequence as set forth in SEQ ID NO: 4, the target gene POU4F2 has the nucleotide sequence as set forth in SEQ ID NO: 5, the target gene POU4F3 has the nucleotide sequence as set forth in SEQ ID NO: 6, the target gene PTGDR has the nucleotide sequence as set forth in SEQ ID NO: 7, the target gene SOX17 has the nucleotide sequence as set forth in SEQ ID NO: 8, the target gene SYT9 has the nucleotide sequence as set forth in SEQ ID NO: 9.

42. The method for screening endometrial cancer according to Claim 38, characterized in that the methylation status of the target gene ADRA1D is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 10-11, the methylation status of the target gene AJAP1 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 12-13, the methylation status of the target gene HS3ST2 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 14-15, the methylation status of the target gene MAGI2 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 16-17, the methylation status of the target gene POU4F2 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 18-19, the methylation status of the target gene POU4F3 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 20-21, the methylation status of the target gene PTGDR is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 22-23, the methylation status of the target gene SOX17 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 24-25, the methylation status of the target gene SYT9 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 26-27; the primers comprise sequences having at least 80% sequence identity, complementarity or at least 10 contiguous nucleotides identical to the corresponding sequences.

43. A method for screening sarcoma, which detects the methylation status of target gene in the cells of a specimen to be detected, and the detection serves as a screening indicator of the presence or absence of sarcoma, characterized in that the method comprises the following steps:

step 1: providing the specimen to be detected;

step 2: detecting the methylation status of CpG sequence of at least one target gene which is at least one of ADRA1D, AJAP1, HS3ST2, MAGI2, POU4F2, POU4F3, PTGDR, SOX17 and SYT9 in genomic DNA of the specimen; and

step 3: determining whether sarcoma is present in the specimen according to the methylation status of the target gene, or utilizing the methylation status as an indicator of prognosis after treatment.

44. The method for screening sarcoma according to Claim 43, characterized in that the specimen to be detected is blood, urine, or an in vitro sample of cancer tissues after surgery.

45. The method for screening sarcoma according to Claim 43, characterized in that the method of detecting the methylation status of CpG sequence of target gene is methylation specific polymerase chain reaction, quantitative methylation specific polymerase chain reaction, bisulfite sequencing, microarray, mass spectrometry, denaturing high performance liquid chromatography, or pyrosequencing.

46. The method for screening sarcoma according to Claim 43, characterized in that the target gene ADRA1D has the nucleotide sequence as set forth in SEQ ID NO: 1, the target gene AJAP1 has the nucleotide sequence as set forth in SEQ ID NO: 2, the target gene HS3ST2 has the nucleotide sequence as set forth in SEQ ID NO: 3, the target gene MAGI2 has the nucleotide sequence as set forth in SEQ ID NO: 4, the target gene POU4F2 has the nucleotide sequence as set forth in SEQ ID NO: 5, the target gene POU4F3 has the nucleotide sequence as set forth in SEQ ID NO: 6, the target gene PTGDR has the nucleotide sequence as set forth in SEQ ID NO: 7, the target gene SOX17 has the nucleotide sequence as set forth in SEQ ID NO: 8, the target gene SYT9 has the nucleotide sequence as set forth in SEQ ID NO: 9.

47. The method for screening sarcoma according to Claim 43, characterized in that the methylation status of the target gene ADRA1D is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 10-11, the methylation status of the target gene AJAP1 is detected by the primer pairs having the nucleotide sequences as set forth in
5 SEQ ID NO: 12-13, the methylation status of the target gene HS3ST2 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 14-15, the methylation status of the target gene MAGI2 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 16-17, the methylation status of the target gene POU4F2 is detected by the primer pairs having the nucleotide sequences as set forth in
10 SEQ ID NO: 18-19, the methylation status of the target gene POU4F3 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 20-21, the methylation status of the target gene PTGDR is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 22-23, the methylation status of the target gene SOX17 is detected by the primer pairs having the nucleotide sequences as set forth in
15 SEQ ID NO: 24-25, the methylation status of the target gene SYT9 is detected by the primer pairs having the nucleotide sequences as set forth in SEQ ID NO: 26-27; the primers comprise sequences having at least 80% sequence identity, complementarity or at least 10 contiguous nucleotides identical to the corresponding sequences.

SEQUENCE LISTING

<110> NATIONAL DEFENSE MEDICAL CENTER

<120> METHOD III FOR SCREENING CANCER

<160> 27

<170> PatentIn version 3.1

<210> 1

<211> 3500

<212> DNA

<213> Homo sapiens

<400> 1

ctccttgccct ccccttttcag ttcccaactgt cctccccctc tcagaaagga agcccaaacc	60
caagattttta ctttttggtca gctgctagct aatccctaga agccacgttg ctttcgtttc	120
aactcactat agtaagtttc caaaaaccaa aataaaagaa gatttaatgg ggaaggcctt	180
ggaagagctg ttccaagct atgattataa aagccttate ttcttggaact gggcaatggg	240
gaggagggag gccacccatc tctaaacatt tctgcagttt ttactttttt ctccaaagca	300
gcttctcacc tagaactcag acatcctgcc cctgtgtcaa ccataaccag tgaacactag	360
ggctatgggt tctccgtccc ctcccagaca cttctgcaaa caggccttca tctccctggg	420
agggtcgaag cctcctcat tctgcaacta tgagacggca ttaccctcct tacagttagt	480
gtatccagca tgggtgcctgc cactgcccag cagccgggtat ttttatgttg gctaactgta	540
tgatttcctt gtgcctctcc ctaccacgtc ctgctattgc tcaagaagct tctcacaccc	600
tctcccatat ctgcacccgg ggtccatacc agccccacac ctctctgcct tccatcctcc	660
ctgttaaaag cctgccctga agaagcccta ctccgtgac atgcccaggc actgctctgg	720
ggccctcact catatttact cagttaaccc tcaggccagg aggtagacat cacttcttat	780
tctcatttga cagttgagga actgaggcac aaagaggttc cgtgtttaat atggggcgga	840
gcctggattc agatgcggag ccagactgtc tcacacccgc cccgtttaac catcctgcca	900
agtgcctttt cccaccctct ggcacttaaa cctcctctct taaaaaggcc agaacaagaa	960
caaggccctt tatttagggt agctatagaa aggtttatcc ccgcacttga tacagggaaa	1020
agtaacagtg ggaaagttgg cgtatgtaga ccagcgtgtc ttgggcaggg tccgagggt	1080
gtagccacag cctgctgtc ctgagcccat cgtaccacgc ctctgcccag cacaggcttc	1140
cgacccttcc tgggctctct tcacgccatc gcactggaca gaggcgtctg aaacctgcc	1200
ctggccagtg gcgtgagaaa aaggagggtgc ggcagatcca tgcgggcagt cccaggaggc	1260
aaccgcagc ggcactgcgc cgtccgggtc gcagtccgca gatcccaggc gcttctgtct	1320
ctctggcggc caaagccggg atcccgaaga cccgggactc acgccttcaa cgcaccgcgc	1380
gcccgaaggc accagcgagt gaccgagaga ctcgggggag agggcgggag gaagaggac	1440

```

gccgctgagg gccaaaggggg aggggggtccg ggagaggagc gggaaggaac gcaaagggca 1500
ccgctagggg agagcgcggg cttgggcacc tgcggagagg cgtgggtggc tgctgcggga 1560
cccgagcgcg cgccagcgcc gcagcccccc ggaccccgac acaatcgctt gtcctgagcg 1620
aagggtccct tctaccctgg agtgtggcgc cgtctctcgc gcccggtcg cccctcctc 1680
cttcttggcg ctgccccctc tcgggtccgc cccccgcgcc gagttgggag cgccgcagtg 1740
gccgctgcct gcaccgcccc gccccggagc cgccgctttg cccgcttgcc gggcacgctc 1800
agagcgccgc gcgcgtagcg ggccccggct cttcggtgct actccacggc cggcctcggg 1860
gagcccggcc gccgccccgg ccaggcagct ccgctctcgg acagccgcgc tccgcgtcac 1920
aggaacttgg gcaggacccc gacgggaccc gtgcgcggag ctgcatctgg agccccgcgg 1980
ctatgccctg tgctccccct cctgccggcc gctcgttctg tgccccggcc cgccaccga 2040
cgccgcgcgc ttgagatgac tttccgcgat ctctgagcg tcagtttca gggacccccgc 2100
ccggacagca gcgcaggggg ctccagcgcg ggccggcgcg ggggcagcg gggcgcgcg 2160
gccccctcgg agggccccgg ggtgggcggc gtgccggggg gcgcgggcgg cggcggcggc 2220
gtggtgggcg caggcagcgg cgaggacaac cggagctccg cgggggagcc ggggagcgcg 2280
ggcgcgggcg gcgacgtgaa tggcacggcg gccgtcgggg gactggtggt gagcgcgag 2340
ggcgtgggcg tgggcgtctt cctggcagcc ttcatactta tggcgtggc aggtaacctg 2400
cttgtcatcc tctcagtggc ctgcaaccgc cacctgcaga ccgtcaccaa ctatttcac 2460
gtgaacctgg ccgtggccga cctgctgctg agcgccaccg tactgccctt ctcgccacc 2520
atggaggttc tgggcttctg ggcctttggc cgcgcttct gcgacgtatg ggccgccgtg 2580
gacgtgctgt gctgcacggc ctccatcctc agcctctgca ccatctccgt ggaccggtac 2640
gtgggcgtgc gccactcact caagtaccca gccatcatga ccgagcgcaa ggccggccgc 2700
atcctggccc tgctctgggt cgtagccctg gtggtgtccg tagggcccct gctgggctgg 2760
aaggagcccc tgccccctga cgagcgcttc tgcggtatca ccgaggaggc gggctacgt 2820
gttttctcct ccgtgtgctc cttctacctg cccatggcgg tcatcgtggt catgtactgc 2880
cgcgtgtacg tggtcgcgcg cagcaccacg cgcgacctg aggcgggcgt caagcgcgag 2940
cgaggcaagg cctccgaggt ggtgctgcgc atccactgtc gcggcgcggc cacgggcgcc 3000
gacggggcgc acggcatgcg cagcgccaag ggccacacct tccgcagctc gctctccgtg 3060
cgctgtctca agttctcccg tgagaagaaa gcggccaaga ctctggccat cgtcgtgggt 3120
gtttctgtgc tctgctgggt ccttttcttc tttgtcctgc cgctcgtga gtgacctc 3180
tcccaccggc cctcctgtgt ctccctgagc ctatggcggg gccctcctgg caccagact 3240
tgggcgacct ccacctgaac ctagaagggt gacttagcaa gtctgagtc tcctaagagg 3300
caggtgtgca tgcaccattt tgtggagtgc caaggaacgg ttcttcatcc tcgccaggtt 3360
cgtttcacag gcttctaact tttctgtcct tcccttcttc tttccaagc cttgggctta 3420
tgctgctggc cctctaaaa ataaaacgtc tgtgaaaatc tgggcgggca tctgcccata 3480
tgtggtcggc agtgtatgtg 3500

```

<210> 2

<211> 3500

<212> DNA

<213> Homo sapiens

<400> 2

acagatgagg agaccgaggg tcggagaggg cacacaactc ggccaggacc ccgagtttagc	60
aagcgctggc ccctgggtcca gccacggcaa ggctggccct cctgccacca cacttccctg	120
cctctggccc tctgccggga gtcttggtgg ggaagtcact gtcttcatcc tcctgcccg	180
gcagagtcca atcctgtgcc tggctcctca agaccgttgg caaagatcct ggaggcctgg	240
gggtgaaagg gctgcttggg ggacttaage cccaagctat ggttcgctg ggagactgag	300
ccccaagcca tggctcctcct ggctctgccc ttccaccccc tcaactggctg cccctcccag	360
ggaggcctca cctgtgaagt gttcccgc cctctcacc cccacggctc tcacatggcc	420
tggggcgatt ccagagctgg cctgggtcaa gcacctgcac agagcacaga gcgaaggctc	480
ggcatggtat atccccgcc cttgcacct ttcccagtg aagggtggca ccagtgtcct	540
ttccaaggcc cggattctgc actgcctca gcctgtggag gattaaaagc agggttttgc	600
cgtggtttct caaggcgta gcgggtctgc agaggattcc gcccctatgc acttctctca	660
gtgaaaggtc cccgccagc gtctgtctc ctttaagtgc ccccatttg tttttgttg	720
ttgtttttgt ttgttttttg caaatacaga ctaaccaggt aggcacagag gagtctggc	780
atgggaaggg agcagtgaac cgccggtgga gagtccggga ggcccagatt ccctggaact	840
ttccagtgc tcctccggag caagggcctg gccaggcagc agctgcgctg ggcatgagg	900
gaccgttggg taattggggg cataggaccg ggcttcgctg ggttcggggc agaagcgccg	960
aagctccgac ccggaacgcg gtgacttcat caacgcagaa gcccgcgag ccgagcagag	1020
gagtccctcg taggcgaccc tcggacagac gtcctgcgc gcccgcgctg gctcagctcc	1080
gcccaggaa acttttcgag cagccccgc tccatgcgc cccaccagc ctttcttcg	1140
ggccgcccc tccccaaagt agctctccg gtccactggg cggccccgta accgggtcgg	1200
aacctcgaac ggcttcgct gccatccgt taccctggca acaccatccg gcggcgcccc	1260
gcggtccaat cctagcctgc ggctctctc gagcctttcg caagggtggg accgggacgc	1320
gaccggggat ggggaagggg gctgcaggag gcccgcctg cgtgtgcgc cctgctgggc	1380
acagcgcccc ccaccaccg cggcgacccc ggccccgca aggtggggcg gcgagcagga	1440
gccggggcca ggccagggg tcgagctccc gttcgagggg cggggaaggc gggtagctg	1500
agccggggcg ggccggcgga gttgggacc gctccgggag gcggggcgga gcgcgcggag	1560
aggcagacgc gaggaggag gcggtgagc agcgcgggcg gctctgcgc gggcgcggtg	1620
ggcgcgggcg gcggggcccc gggatcccc cgcgcctcct ccgcgcggcg ccgcccgcg	1680
gcgtccccac gcccgcgct ccacggcgcc ctgcggcg gcgcctctcg tgccgcctc	1740
ctgccagtct ccgggcccgc gccgtctgca gagcgagcgc tcagacggag cccccggca	1800
acttgagtgg cgcgcatcg cggcgagcc tctggcagag cccccgacc cggcagcgcg	1860
gaggggactc gcgtccgtcc gcgtcgcgc accccaaacc ctaagcagcg ccgccccatc	1920
ggcgcgagc tccggctgga ggcaagagc gcgcgccggg agacacgcac cgtgagcggc	1980
agcgccgccc gcctccctcc tcgcccgc ggaggcgcaa gccgcggctc cccagccctt	2040
tgtctgcgccc cgacagcgcc ggaacagcc ccgcctcgt gccgccttcg ctgtgccgc	2100

ggcgaggagg gccgcgagcc ccgcgccccg gccggaggat gtgcgcccc gcgggcccgc 2160
 cagcctgagc catgcgcccc aacggcggcg gcgcgcccgc cggcatggag cccgcgcgg 2220
 ccgcgctctg actcgtctgt cgcggcgcg ccggcggcg gcgggaggcg gcggaccgag 2280
 agccggagac cggcgccgcg ggacggaagc gagcggcgcc gggcgccgcg cagatggcct 2340
 gggcgagcca ggtctgaggc cccgctcccc gaaacgtgac catgtggatt caacagcttt 2400
 taggactcag gtgagcgacc cggcggcgcc cgggtgcgtg tgggcgcgtg ggtgccaggc 2460
 tgggcggaag cggcgctttc ctctatgttg caaatcaagg gacccctctt cgcttcccgc 2520
 aagcgggcaa cggggtgcac cggtagccgc aaagggcgcc ccgcccggag cctggagcag 2580
 caccgcggcc ctggcgggga gcggccgggt ctccagggtt ccgcgcgtcc ggggtcgggg 2640
 cagcggcgcc cgcggcagca acccgggaag tggggccggc caggcgccgc cgcagctcta 2700
 ggagccagca gcgcagtgtc ctggccgggt gcccgcgcgc gcctcctccc cggggcccgg 2760
 ggcgaggcgc cggccgctgg gcgcggcgcc cgcggggcc ggggctgccg gggaaagcta 2820
 aagctccggg ctcccagcga gagcttcgca ggcgaggttg gaggaacca cagccaaaca 2880
 gccactccgc tcccccttct ctttctcgg gccccgggg ctgagcaggg gcctcccagg 2940
 ctcccagctg ccgaccagc tgtttgcggg tgacctccgg gcccgacggg cgctcacagc 3000
 tggcgggcag ctggggcggg agagctgggg ttcttgggga gctccggcgg ccaccccgt 3060
 gtaaacacac acgcacatac gccgcgggc gcgcccgggg cttgtctgtg tctgggactc 3120
 cagggccaga tggaagaggg ggttcgagcc tagagccgt ggtgggggtg tccagaaaga 3180
 cccttctcgg caaactttgc cagcccgcc gggttctcgg gcttctctgg cttctgcctg 3240
 ggggtggcca gggcccacca gagcacagct gtcgtttttg ctgggcaggc tgcctctgag 3300
 ccctgcctt cctgccgggg cattaccga gtcgtgcat ttgggtccc ggttggaacc 3360
 gcgagcgggg aggacagagg tggaggcgga gagcagcgtg cggttctcga gtttgtccac 3420
 tgggatgcac tgcgctccc cgttggggac gaaaaggcca gtagttgtta gccgctgct 3480
 tgagccgccc ccactcaggg 3500

<210> 3

<211> 3500

<212> DNA

<213> Homo sapiens

<400> 3

aatcttctta tcaactgcctg tagattagaa attacaataa tacctatctc caaagataaa 60
 tgaggtagt catgtcaagt gattagcgca taactcccat aaaacaagca ctcaataaat 120
 gctagctact attagaatta agacagcaaa gtgatgccag ggtaatggta acaacttcat 180
 aggttggtgaa tatttaata gtttaacccat gccagggtgct tgatacaaag ttggcagcta 240
 ttattattat ctgccgtaga attggtttaa ggtttctagg gatgggacta gtttggggac 300
 aaaatatttt ctggtttggg ctaagatcca cagaacctaa tgatcagttt acagcctgag 360
 gaaggaagtc agttataccc tgatcagggt gggggtcatt gtggtcatct agacattcta 420

tggtctgggtg gtggtggagg gcactcacct tgtgaacact cggacatggt gaattggcat	480
tggcattgct gttgaaggac aactcagccg tgttcttagc catggccatt taggcctgtt	540
ctgatgcagg gttctgatcc aaggtaccag tgtggtccct cagggaagta ctggggatcg	600
tcacttatgc ctgttctgga catggtcacc gagaactgtc ctgtaggcat tcacttagga	660
atcattcgaa gtggaattgc tcctggatac gttctccttg tactctgttt cctcctccta	720
gtgtctctgt gtgaagaagc cctcctcact cagccctcgg cgaccctctg gtaccctgga	780
cagctccccg gggagcagtc taccgctagg cggcggctgc taagagagga accctcctga	840
cgcggagtct gccgctccgg ggctcgtctt ccggcaggcc cggggagagg tggggtgaca	900
atgggttggg gtgcgcgcgt gcctcatagg tgcgagacag agcgagccgc cggggtgtga	960
gtcagcgcgc tgggggctaa gaagctgggt gaatagtcac ggaatctcac tcacgctcgg	1020
ctcctccacc catcccgtct acagcgcgtg tcccagtcga gggcgtgcgt gcgctcgggtg	1080
tccgattccg ggctgtgtgt gtccatttgg cgagatgtcg agagcggggg gagtgtcctt	1140
gtcgggtgat ctgggcccag gttaggggac ttctcctccc ccccccgcg tgggtgtggg	1200
ggtgtgtccg ggctagggcg cgtgtgcttc tgtgcctgtg cgtgcgtgtg cgggtcaggg	1260
tggtgggacc gcgcatcagg gcagggtgcc tgcgtctgcg tctgggtctg tctggtctgc	1320
atgtcggcgc gatctcgacc tggattcgtg tccctggatg tcgagaggcc agcgtggtgg	1380
gggtgtccag cctcccggag gagtactatg ccttgacacc ttcgtttcac cgccccaaag	1440
ctggcctggg gctccgtagg gagtggcctg catggggagg gcccgctgc tgtgtttctg	1500
ggaggggtaa gagagtgggg gcgcaggggg cgggccaggt ccctgggcgc ggcgcgggct	1560
cgggggaccc gcgcggctga cgtcaggcca ctcttaaat agagccggca gcgcgctccg	1620
ctcggcattt cccgaagagc cagatcgcgg ccggcgccag cgccaccgtc cgggtccacc	1680
gccagcccgc acagccgcgc cgccgccgag cgtttcgtga gcggcgctcc gaggatcagg	1740
aatggggctt cgggcgctgg gcgcgctccg aaccgggcgc acgtaagagc ctgggagcgc	1800
ccgagccgcc cggctgcccg gagccccatc gcctaggacc gggagatgct ggaaatgcaa	1860
ccgcctgttc cccgaggagc cgctgcccc gggaccccct ggcactgtgc gcaccctggt	1920
cagcagcccc cggagaagac ggcgccccca acgcccagacc cgcgtggccg tggcagcgcc	1980
acgcgagccc tctaggcgac cgcagggcca cagcagctca gccgcccgtg ccccctcgga	2040
aaccatgacc cccggcgcgg gcccatggag ccatggccta tagggctcctg ggccgcgcgg	2100
ggccacctca gccgcggagg gcgcgcaggc tgctcttcgc cttcacgctc tcgctctcct	2160
gcacttacct gtgttacagc ttctgtgtgt gctgcgacga cctgggtcgg agccgcctcc	2220
tcggcgcgcc tcgctgcctc cgcgggccca gcgcgggcgg ccagaaactt ctccagaagt	2280
cccgcacctg tgatccctcc gggccgacgc ccagcgagcc cagcgctccc agcgcgcccc	2340
ccgcgcgctg gcccgcacct cgctctccg gttccaacca ctccggctca cccaagctgg	2400
gtaccaagcg gttgccccaa gccctcattg tgggcgtgaa gaaggggggc acccgggccc	2460
tgctggagtt tatccgagta caccggacg tgcgggcctt gggcacggaa cccacttct	2520
ttgacaggaa ctacggccgc gggctggatt ggtacaggta aggaccagga gctccgctcc	2580
gtgcgcgggg tctctgatcg ctccatttgg gagagccatc cgtctcttgt gttttctctt	2640
tcttttaacc caactcattg tatgggttca ggctgacaca cagggccatg gggggctata	2700

gcagaattta cccagaactt cccagtata atctagacgg gcagtttctg gaactgcaaa 2760
 gggcgttccc tegtactgg agtcgttgga aaaggattat ctccagtcaa acctaagtgc 2820
 cagctaaagg gctaactccc tctgtgacca gcccttaggg tgcccaagga agggacaggc 2880
 gaggacctgt gctgcctgaa cacggcacca tcctaaccct ctgtaggtct ttgctggtac 2940
 ccagccccctg aaggaccctg agaaagataa ggcagttcag agacccttg cagcaaggct 3000
 ctgtttggga aaggtcccca gagttcaggc caaatgacag tgcacgcca gaggtctcca 3060
 gtaagaaaga tgccttaggg agtctcaatc tcaaaccag gtatttgctg ctgtactggg 3120
 gctgagaccc ccagtagctc tggccctggt aggtggtctt tgagtagtgg aaagagccct 3180
 ggattcgagt cttgggtctg tcaactaagc ttgagcaagt ttcttaaact ctatcagcct 3240
 ctattttctc atccatccca atgggcagga aaacagccct tgccctgtat accttccaag 3300
 gcttttctga agtgccttaa aggtgtaaaa aaggcacttc actttaagt atgcttctaa 3360
 accagcagcc aaaatgtgga atttgaaggt gggccctgcg ggtgaaggct agcaagggtg 3420
 ctaggggcag ccagtcatgc atagactgtc tatgcttccc atgcatgcca gggaggagaa 3480
 ttatccccac tgggggagtc 3500

<210> 4

<211> 3500

<212> DNA

<213> Homo sapiens

<400> 4

cactgaataa gcttcaacta gtgcagccaa cttacggagg atctgttttc tcaagtgaaa 60
 aaaagacaca aggttaaaca aatcatcttt ttttaagatc tcttcagtt ctgactacat 120
 ttgatecccc tcatcccaa gtagtaagtt atacctaaga gggaaagagg agggaattat 180
 catttgaac tcctactcac ctgtgccagg agagcactgc tgtgactgat ttccctgatt 240
 tcatcctcac cacagtccta acagattagt attgttaaag tccatttaac aactaagaaa 300
 gctgaggctc aggaaggtea agcagtttac tcaagatcat attctcagta agccgcagag 360
 tctggattga aacctggtct ttctgtttgg gtcgactcaa catTTTTAAC cgtattgttt 420
 gcctctaca tgccttcat ctacagacatt aagaatccta cctattcaat gcttttcatc 480
 ctccgcttta aagagataag tgggtgcaca actTTTTTTT tgccctgaaac atatcatcta 540
 aaagttaagc aatgaaatt catttaccag ttacaggaat ctttttctta aatcactgtt 600
 aatgtctcac aggaattag ctcttcagt gaaatcagca gcctccctgc atccttttgc 660
 ccctgtctc ccctctcttg gatgcaaacc tggcgaaaag aagggaacac tgcttggggt 720
 cagegagctg agttccagct ccgaatgtac catTTTtacc ctcgggagtc ttctccctt 780
 tctctgtgag caaaggagt ttgggccaga ccgtcttaag gattcttccc caggtacaag 840
 ccgactctg gcggctttcc tgggcaagg agtgtctccg ccttgtctct gccgcaggtc 900
 cctggttaaa ttgtcaattt ctctgcggag gctgctcact gcatccgctc cctccacccc 960
 tagccctgta gacccttct ctttcccta cttgggaaaa gtgaagcccc ttatccttgg 1020

atagcctttc accagacaac cgcagccgtc cgctaaattc ccctactggc gggacgcgcg	1080
ggcggggggc tgccccgggg aatgcgaggc tgcttccctt ctgcgtaatc agggtagcga	1140
gcctccagtt ctctaacttt ctctttctct aagagggaat ttcgagaact ttaagacaaa	1200
taagtgacta tatagatgaa gacatgaaac ctctctacac agtgaactcc cccacgctac	1260
aaggctccca gggatcccag gcctttctcc gcaatgcccc gccgggtccc ccgccccaac	1320
tcctttctcac ggcaggatcc cgcgccagga cgctcgcaga gcccagatg tggcaccagg	1380
cgcgccacaa gtccaggtec cgctattttct gctccatcgg agcccaggtc ggagggagtc	1440
agcgcgtcct cctcgcacag gagcctggcg cgcggctcgg tcgcacagag gctgaagaaa	1500
ggtccgcact gggctcgagg cccttcttgc cggcctcccc acgccgggcc taggctcccc	1560
tccttcccgg ctcccgctc ctcccgtagg ctgccaggcg gaccagcct gcctctctct	1620
ctgccttcac taccgggtca agctgcggag ggagggaggg aggcagcggc gaagccctcc	1680
gtggctcccc acccggcgcg cgcgccctc ctcccctgcc tcctcccgtc tgccagtaca	1740
gtagaactag tacacacaca cacacacaca cacacgcaca cgcaccctgc cactgcagct	1800
gccatggata tcagctaaca acacacaccc aggcgcgcgc gcgcgttccc actcgcacca	1860
cgcaggagtg gccccggca tccctaccct ccttccccac ccccaccaca cccgctcacc	1920
agctcggcta ctgctcgtc cggctgccgc cgcgcgcgc gccgacgcca ccaccactgc	1980
ttcctctgct gcggggccac agccttgagt gtcattcaag ggacagcaca acctcatcca	2040
agctctccta cctctgcca gccgtccctc tcctcctccc cattcctcgt ccacactcca	2100
tccaaagaag agggaaagca ccgaatagag gggggcgaag gcaaagtctg ctgttcttcc	2160
ccctgggccc ccttgctcct ccctcctcat tctctacca ccagcccccc taaccccaag	2220
gagcccagga actgaggcga ctgcgccac tgccatgtcc aaaagcttga aaaagaaaag	2280
ccactggact agcaaagtcc atgagagtgt cattggcagg aaccggagg gccagctggg	2340
ctttgaactg aagggggcg cgcgagaatgg acagttcccc tacctggggg aggtgaagcc	2400
cggcaaggtg gcctatgaga gcggcagcaa atttggtgtcg gaggagctgc tgctggaggt	2460
gaacgagacc cccgtggcgg ggctcaccat caggagcgtg ctggccgtga tcaaacactg	2520
caaggacccc ctccggctca agtgtgtcaa gcaaggtgag agcagcggct tgctcagtgt	2580
tttgccgggc ggtgggaccg ctcggggcgc agggcaatga aagggtggcc gcgcatgttg	2640
aagggggtgt gttgcgcgat gatggggtgg gggccagaga gcacccgcag tgcaagtgag	2700
tttcgccggg gattcgactt gggggctaaa gggaggggag gggcaggttg tgggtgtggcg	2760
tgcaactttg tttgctcagt tagaccctcc cttttggaag gtgctcggcc tgggtctgacc	2820
tcctcagagc tgctggggca aattgaatgt gcgtcagtgg catcacccga agcggatgaa	2880
gagcttttgg ggaaggagg aaggaagaaa agaaagaaag aatgggagga agggagggaa	2940
agaaggaagg agcaacttca ggggtgcagcg gcatcaccag cgggtctggg aagagaaggt	3000
ggtgggggtga gcggagaact gcgtccagcg tttctggggc tgggctgggg gcgcctgggt	3060
ccccagctgt cccttaggga tccgtgagcc accgctggcg aagaaaagaa gggacaaatt	3120
gctttgggcg ctttgacggg tcttctgtaa cttttcccct tcttactcc gtgtccccct	3180
ccccgcctca cggctcgtgc atgtgggcat cgcgcgtcac gtgcgtactg actaaccct	3240
gcgctcacc ctagccagcc cgggggagga ggctccggaa gaaggcgcgg tgctaggagc	3300

gcagtctagt gctgggcggg ggtcggagga gatgaatggt tgtcggagga gatgaatggt	3360
tgtecgcatg gactttactc aggggttgcc ctcatagagt ggaagtcctc tgtggttggg	3420
ctctcctctg gctccgattt ggggggcgtg ttttggggga ggagctggat gaaaccctgg	3480
ccggttccag cccaggctcc	3500

<210> 5

<211> 3500

<212> DNA

<213> Homo sapiens

<400> 5

cattcacgtg aacactcccc tttccctacc ccatgtccag gtttcgctga gtcacaccc	60
ggcaacactg ctgctaggag ttcccttcgg ctactattta ttattttcct ccacacaggg	120
gaagagaaag ggaagcccgaggatccag ggaaagcaga aggggggttaa ggaccatgga	180
cagagcccggt cgcgcgctcg ttgctgccgc cttccccagc actctggcgg ctcttgagga	240
cagcggtecc atcttgaaac cgctattccg cccggctgag gtcaggggtg gacaggcgt	300
cccctactct ccaccgccgc ttccgggagc tgaccacccg agggttcccc ttttccactc	360
tccttcccac tctgtttttg tcccagcgcg cgccagcgcc tctcaggcct gccgcctgct	420
ctcgcacctg ctcgccttcc ccaggcgccc agtgccctgca cctgctcccg gtcaaccccc	480
gtccggattg ggccaccgcg gggttcctgc gtcgggggtcc cggggccttc tcaccctcgc	540
ctgcaccctg ctccttcgcg tctctagga ggtgacagca gcccccaaca ccgcgggaag	600
tatagagaaa atgggatcca gaaggagagg aagtagtgtg tgtgtgtgtg tgtgtgtgtg	660
tgtgtgtgtg tgacagagag agagagatag atagaaagag attatctcct tttgcaactg	720
gaaccaagag tgtgtgtcca tctctaggaa aagtggctctg cactgggact gggacagaag	780
tgggagtga gtgtcagcta aaaataggct ccgcaccgag aggtgttgga aatgaagata	840
agtgaggttt gtgccagccc ccgagggtgt gtgtgtgtgt gtctgtgttg tggggtgtat	900
tcagcagcat atgcgtgtg taatttctga ccttccctct ccctgtcagt tgccccctct	960
tcctttgatt gtggctaattg aagaataata aatccagggg cagggtttgc cagtggatcc	1020
ttccaagact caactcgaac tgtactggat acagggagga ggaggaagag aaaagggggg	1080
caagaggagc gtgtgtgtgt gcctgtgtgt atgtgtgtgt gtgttgtggg aggggtgggg	1140
acagcgggga gggggaggag tcgcatgcgc acagacgacc cgagcctgct ccgcggctgt	1200
ccaatccgct gagagctgcg agaaatcgag tgagagaaag ccctgcagcc cctccgaccc	1260
catgtctctt tggcaccagg caccgcgcgg gccgtggggg gctcgtagcc gaacgccgac	1320
ctccgctcgt attgggctgg gagttcagag ccgcgcgcag aaccgggtt ggccgcaacg	1380
tctgtgttct cagcgggtggc cgggaacctg ggatcagggt cacctgagct gacgggtg	1440
gggcgggccc agtgggggtt gaagcctgga acttagtggt aagcaggagg ctaggaggt	1500
ggcagccagg taagaggcac tcttacctac ccaacgctgg cttgggcccgc aactttat	1560
gggagtttct ttttccggtg agacagagac ccggcagaag aagcgggagg ggctggaggc	1620

tggtccttag gtaggcactg cccggcgact ggagcgcgga cctggccatt tgggtggggt	1680
tgagtggggg cgcgattgtg agtagcagcc gcgggacgct gcgaaggggc ggcggcaaca	1740
gagcacgggc gggggcagaa aagaggcggc ggagggcgcg gtgggggagc gcgaggcgag	1800
tgctgagaga gcagaaagga ctcaagcctg aggggagtag agaggaagaa ggggcaacgc	1860
gagaaaccga acaggagccg gcgtttcctg gcaagggagg gcggaggcgc gcgggagaga	1920
gggagagagg gagggcgggg ggcgcggggg taggcgcggg gagaggggag tataactcgc	1980
cggccgcgag gagcgggggc agtttcgggt gccgaggtct gcagctagcg gcaagcggag	2040
tcaggcatcc gttcagactg acagcagagg cggcgaagga gcgcgtagcc gagatcaggc	2100
gtacagagtc cggaggcggc ggcggggtgag ctcaacttcg cacagccctt cccagctcca	2160
gccccggctg gccccgcaact tctcggaggg tcccggcagc cgggaccagt gagtgcctct	2220
acggaccagc gccccggcgg gcgggaagat gatgatgatg tccctgaaca gcaagcaggc	2280
gttttagcatg ccgcacggcg gcagcctgca cgtggagccc aagtactcgg cactgcacag	2340
cacctcgccg ggctcctcgg ctcccatcgc gccctcggcc agctccccca gcagctcgag	2400
caacgctggt ggtggcggcg gcggcgggcg cggcggcggc ggcggcggag gccgaagcag	2460
cagctccagc agcagtggca gcagcggcgg cgggggctcg gaggctatgc ggagagcctg	2520
tcttccaacc ccaccggtgc gtatttctgc ataatacccg cttaaaggca cattttgaca	2580
gcccccttta tctgcttgat gtttttttca tgtctgcaca gcaaatacc ccacacctcc	2640
aaccaatddd cccctctctc tctcttaagt attcagcagg tcttgccctt catattaatt	2700
tttatgacct gggatgttgc ctgtgcgcgt gttgtgttgt gtttcgttgt gtctacaggc	2760
tcactttcct cctcctcctg cactctcggc ttctttctgt ggcttcctc tttttctctt	2820
cacctctggt ttcaggatta ttattattat tattttaacg atctgggaat gttgtaggcg	2880
cggcgacggt gtcgagccct gggccggggc ttccggagag agggcgtaaca attccctgct	2940
gagcgtaatg tgtgccttct attacaatt gcagagcaat atattcggcg ggctggatga	3000
gagtctgctg gcccgcgccg aggtcttgge agccgtggac atcgtctccc agagcaagag	3060
ccaccaccac catccacccc accacagccc cttcaaaccg gacgccacct accacactat	3120
gaataccatc ccgtgcacgt cggccgcctc ttcttcatcg gtgcccatct cgcacccttc	3180
cgcgttggcg ggcacgcacc accaccacca ccatcaccac caccaccacc accaaccgca	3240
ccaggcgctg gagggcgagc tgctggagca cctgagtcgc gggctggccc tgggcgctat	3300
ggcgggcccc gacggcgctg tgggtgtccac gccggctcac gcgccgcaca tggccaccat	3360
gaaccccatg caccaagcag cgctcagcat ggcccacgcg cacgggctgc cgtcgcacat	3420
gggctgcatg agcgacgtgg acgccgaccc gcgggacctg gaggcattcg ccgagcgctt	3480
caagcagcga cgcataagc	3500

<210> 6

<211> 3500

<212> DNA

<213> Homo sapiens

<400> 6

ccgcagtaca gagaagttga gaatatctcg tggctctcagc cagcaagagg cagaggcgca	60
ttttgaatct gaggccaggg cctgagcgct atggcaccag gttgtgaggg agtttactga	120
gcaccaattt cgtggctcaa tgcttttctt cttaccctaa ctctgaacgt cttcaccaga	180
atccaaggag gcagacagta gtgcaattcc atttaagagc cgccgaaacc gaggctcaga	240
gggcttttagc gaaagggttg cgcttggctc taggcacctg ggctgagtct ttttcccacc	300
atcgcagggc gggaaccagc ggagggggct ggctcggatg gggagaaaag caactggagg	360
gcgccgaggg gaagaggag cccggatctg tcagggcgtc ctcttggact aagggatgtt	420
cccctaaacc acaccacccc acctcgttca gattctggga aacccggcac gcacataccc	480
tgcacaataa caggcagggt gaggtctcta agccccgaag atcgctctct cagcggaggc	540
agtggccctg acgagggggt acagctgcac gcgcgggggt tctctccgaa ccggagtgca	600
gcgtagtcga ggtccaggat tccccatcca ttattcacga tgtttactag agcggggcaa	660
gggagaggaa agaagaggga agtagagaga aaaagaggct aggggaggtg gaggcgggca	720
gtgctaacct cgagagccct caagttccga aactttgaga aggaagacca agaggctaag	780
gcgcctggga agcagcaggc cgtcagtaaa tttttgtaag atggatggat aactgggtga	840
gtgagtgaat gggctaata ttagccccctc tgatccttgt tttctctatc tgtaaaacgg	900
gataacatca cctactccat acggtgggta tgagaatccc atgggcaaac tctaaattgt	960
ctagcacata ttaggaactc ttaaacggta gctgttgtca cgaggaatgg gcttgcaagc	1020
tctggctgcc cagcagaaat gcaactgaagg actcccaggc ctggagggcc atcctgaaca	1080
gtcgtatatt taaaaaaaaat actccacaag ctctccttaga cgggagggtt ggaggaagag	1140
tgggccaagt tacatccctc aaatgaaaga aagaaaggca agcgtgggga ggaagccacc	1200
ccggactgag aaggcagtta ctgcccctac ctctaccccg gagcgcggtt gagggaggtg	1260
gggcaggggt cacctgggcc tcgttctggc agcccctcac cctctccagg gcccgtctgg	1320
gcgcttggag gcgcctctc gctgcgccgc gggaccggac tctggtggac agcttgggcg	1380
tgaggccagg agcgccttgg aaatgggcag tttggcggca gccgggccga cggagtgtgt	1440
gtgtgtgtgt gtgtgtgtgt gtgtgtgtgt gtgtgtgtgt gagaggggaa gttggagtag	1500
ggtcaacttc ctgccccagc tcagcccagg gctacccttt tatccaggca gttcagactg	1560
ggacaggacg gagaggttgg gacttttggg gtggcatggg ggaagggaag tccacgaaga	1620
agaaagaatc ggaaaggtct ggcgggttgg agccagcggg gcggggcgga ctgggagagg	1680
ccaggccagg cccgggtata aaggctgttg agggggcggc cgccgcgggc gcagaaaggc	1740
gcgcgcctag ctgctgtctc tctcacctc cggggccgcc cctgcgagtc cccggcgcgt	1800
gagcacgcct gcgcgcgcc gggcccttcc tggcaggctg cttgtaagat gagtgaagaa	1860
gcaggtgggg gagaggggag gcagcgagcg agagggcgag gggagcgcgg gcgctgagca	1920
gcgctcactt ggagagcggc aagcaagcta gacaagcctg attccatgtc acccgctgcc	1980
accctgccag gagcgcgaag atgatggcca tgaactccaa gcagccttcc ggcatgcacc	2040
cgggtgctgca agaaccctaa ttctccagtc tgcactctgg ctccgaggcc atgcgccgag	2100
tctgtctccc agccccgcag gtacgtagtg gagcataatt accgctctaa ggcacatttt	2160
ttgacaggca ctagcttcat gtttttttca tgtcgccag aacaatcgcc gctgtctgaa	2220

cccctctcct tgtctccccc gcgttctctc ccggcgcgct ctctctctca ttcattgtctc 2280
 tgatccacac gtctgttcca gcagagccgc tgcctccgta ttaattttta tgacctgggc 2340
 tttgaggaga ggcatctcgg ttgcttgaaa atgtgtttta atcctgtgtt gacagtattc 2400
 cctactgacc gtgctgtgcg ctttctcgct tgcagctgca gggtaataata tttggaagct 2460
 ttgatgagag cctgctggca cgcgccgaag ctctggcggc ggtggatata gtctcccacg 2520
 gcaagaacca tccgttcaag cccgacgcca cctaccatac catgagcagc gtgccctgca 2580
 cgteccacttc gtccaccgtg cccatctccc acccagctgc gctcacctca caccctcacc 2640
 acgccgtgca ccagggcctc gaaggcgacc tgctggagca catctcgccc acgctgagtg 2700
 tgagcggcct gggcgctccg gaacactcgg tgatgccgcg acagatccat ccacaccacc 2760
 tgggcgccat gggccacctg caccaggcca tgggcatgag tcacccgcac accgtggccc 2820
 ctcatagegc catgcctgca tgcctcagcg acgtggagtc agaccgcgc gagctggaag 2880
 ctttcgccga gcgcttcaag cagcggcgca tcaagctggg ggtgaccag gcggacgtgg 2940
 gcgcggctct ggctaattct aagatccccg gcgtgggctc gctgagccaa agcaccatct 3000
 gcaggttcga gtctctcact ctctcgcaca acaacatgat cgctctcaag ccggtgctcc 3060
 aggcttggtt ggaggaggcc gaggccgcct accgagagaa gaacagcaag ccagagctct 3120
 tcaacggcag cgaacggaag cgcaaacgca cgtccatcgc ggcgccggag aagcgttcac 3180
 tcgaggccta tttcgctatc cagccacgtc cttcatctga gaagatcgcg gccatcgctg 3240
 agaaactgga ccttaaaaag aacgtggtga gagtctgggt ctgcaaccag agacagaaac 3300
 agaaacgaat gaagtattcg gctgtccact ga 3332

<210> 7

<211> 3500

<212> DNA

<213> Homo sapiens

<400> 7

taccatagaa gggcttcagg aaatggtgaa cagcctgaga ttgatgtaaa gtgtgtgtgt 60
 gtgtgtctgc gtgtgtgtct gtgtgtgtgt gcctgtgtgt gtgtgtgtgt ctgtctgtct 120
 atggaggaga ccacagcttt catcaaattc tcatgtcttt tggttatggg gcctgctctt 180
 cttttcactt cattaagtcg agtggggctc ttctaaacct attcttatgt gctaggggct 240
 agagatggga atgagagaga gtaggtagaa gacaaggga ctaactctat acaaggcctt 300
 ctattgagtc aatataagtg aaaggcttag agagtgtcca acctgcatca ggaccaataa 360
 atattagctc ttattattat tattacacta tgccaaagca cttcaagttt tctcaacctc 420
 acaacaacct cacaagttca gcataagtct catattccat taggttgaac aactaaccca 480
 gggtcacaca gccagtgtg gagttcagaa ctatctaatt ccaagcttag attcttcttt 540
 tccacctgtt ggcctgaatt actggccaga ctttcagtct ggaggcagcc tctctgtcta 600
 cccttcagge tttcacatct aaatcccaag ggtcttgctc tttccctgag tctgtccatc 660
 agaactggca tgaggcctaa aaatgagccg tttcaagccc aggcatcatc tactcactta 720

cataacaaaa ccttagtcat cccactgaga ttccacactc aaagccaatt tctctcacag	780
ggcatcgaat gctagttaaa gatataaaat cacgcttate acaattaact cccttgccctt	840
tatgatgcag ccaagtcaaa gcccaaacag gaataaattt tttctagtag ccacaaatca	900
gaggagttag aaagctctat gccaaatcta ccattttctg atttcaaaat ccatgctaaa	960
aactgcagtt aaacatcagc taccaaaaca cccttctatc aaataagaat catggtgatt	1020
gcatgaattg agcactttct atgtacttgc tctttacgtg ttatttctat gcctcagaag	1080
agccaagcag gccagataga tgttactgct tgagaggcta agcaagtccc ataaggtcac	1140
acacacagtg aggagcagaa cctggactca aaccaggcc tatctgatga cagcaacagt	1200
gctgctaacc atgcccttcc cccagctct ctacagtcaa tgtgattcat ggcacccagg	1260
accaacaccg gctcttggct ttcccacaaa ccacttcctt gaaatctgga caacttcttg	1320
ggaggaggag tcatgggaac aggacagatg aactccaaaa tagaagatcg ggtgagaggt	1380
ccggtctgc tacttctgta gctctgtcac cacgggcaga tcacttaact ttccaaggcc	1440
tcagtttctt cgcctatgca atggagatga ccgtgaatgc cccaaattgc gctgatctag	1500
tagagaagag gagctaaggc tcaggggctt tccagacgtg agttatcttt acctttcctt	1560
gactagctaa ttcaagacaa ctaggtagaa gccctttctc agcctcccct cttcgtcat	1620
ctttcagatt cttggccacc ccagttcaaa caccagcacc attgccctcc tctcaggtgg	1680
ctgctgctta atttcccctc cacttttagta gttcttctct tgccctcgcta gaaggactgg	1740
tggttggtgc ttggaattct ggctattttc ctctgccgt tccgactcgg caccagagtc	1800
tgtctctact gagaacgcag cgcgtcaggg ccgagctctt cactggcctg ctccgcgtc	1860
ttcaatgcca gcgccaggcg ctaccctgc agagcgtccc gcctctcaaa gaggggtgtg	1920
accgcgagtg ttagatagga ggttcctgcc gtggggaaca cccgcgcc ctcggagctt	1980
tttctgtggc gcagcttctc cgcccagacc gcgcgcggag ctgccggggg ctcccttagca	2040
cccgggcgcc ggggccctcg cccttcgcga gccttcactc cagccctctg ctcccgcacg	2100
ccatgaagtc gccgttctac cgctgccaga acaccacctc tgttgaaaaa ggcaactcgg	2160
cggatgatgg cggggtgctc ttacgacccg gcctcctggg caacctgctg gccctggggc	2220
tgctggcgcg ctcggggctg gggtaggtgct cgcggcgtcc actgcgcccg ctgccctcgg	2280
tcttctacat gctgggtgtg ggcctgacgg tcaccgactt gctgggcaag tgccctcctaa	2340
gcccgggtgg gctggctgcc tacgctcaga accggagtct gcgggtgctt gcgcccgcct	2400
tggacaactc gttgtgccaa gccttcgcct tcttcatgtc cttctttggg ctctcctcga	2460
cactgcaact cctggccatg gcaactggagt gctggctctc cctagggcac cttttcttct	2520
accgacggca catcacctg cgcctgggcg cactgggtgg cccgggtggt agcgccttct	2580
ccctggcttt ctgcgcgcta ctttcatagg gcttcgggaa gttcgtgcag tactgccccg	2640
gcacctggtg ctttatccag atgggtccac aggagggctc gctgtcgggt ctgggggtact	2700
ctgtgctcta ctccagctc atggcgctgc tggctcctgc caccgtgctg tgcaacctcg	2760
gcgccatgcg caacctctat gcgatgcacc ggcggctgca gcggcacccg cgctcctgca	2820
ccagggactg tgccgagccg cgcgcggacg ggagggaagc gtcccctcag cccctggagg	2880
agctggatca cctcctgctg ctggcgctga tgaccgtgct cttcactatg tgttctctgc	2940
ccgtaattgt gagtccccgg gcccagaggc agcagggcac tgagactgtc cggccgcgga	3000

tgcggggcgg gaaggggtgga gcggatcggg atggacgcgg cgccaggcga gctgcgccct	3060
gggccaggaa ggtttgctgc tgagttcccc aaattggatt cttccacag ccccagata	3120
taactcagtt tgcggagcga aatgaggga agttagagaa aggaaggga aggctgagcc	3180
cggcggtgtc tccctagccc agcaaaaccc tctccatgtg gcagaactcc ctcctctctg	3240
cttcttctg gggagatctc gaggtcattt ttgcgcctta ggaggagcag aacttagttt	3300
ctccttgga acaggagtct tctacttccc gacggctggg tgatgtttta tttgttaga	3360
cctgctcatg acttcagtgg taccagaaat gggcgaatgg cgtctgggac gatcttctcc	3420
ccggtgttgg catagaaagg gaaaaagagg ttaagccag ccagagtgat ttgcagatgc	3480
atagtttta ttttgaaaaa	3500

<210> 8

<211> 3500

<212> DNA

<213> Homo sapiens

<400> 8

ttaagagaaa attctgcttt gagagctttg aaaaatattt attattatcc agaaaagtta	60
gaaaagatct caaaaaaaaaa aaaaaaaaaa acagcaaaaa acaaggtact acggggttaa	120
tttgtagatt gctctctctc ctctatagtt tttgttgctt atttaatcat ttgcaatgtg	180
cttttgcttt atactgaagc ccattttttt ttcagaaaaa ataaagcttt aaaagtacat	240
catcatttta atttgtctaa aatcaaccgc tttcaaaact accaactaga agtaacacct	300
ctctatgatt tctttatgca gatttaattt ttttcttgt ttgaatctta gagaccagc	360
aactagaaac actttcttaa ctgtccctt agccaaggct tcacagatac ttgcagaatt	420
aaagataagt tggcttaaaa caattgtgta agagttcttt tgagaaaaag caatgccaga	480
gaaactgaag gccaggagtt tgcaaaagtt ttgtattttt atggatgcca ctaataagca	540
agactggaca gacggtcttg ttgttgtagt atcacactca aagcagcagc attttacttc	600
tcagattcca ggtgtaagct ctactttttt atcacgcctt cataataaag aaaatctggt	660
ctggagattc gtatattgat ttctttgcaa agttatctct aattatgcag gaatggctgt	720
tagttgccct caaaaaccaa cacaataca caaacacaac agcctggctt agtgattatt	780
aagagctgca agtctgaagg cggactgctg ggtgtgaatt ccaccttctc aacgctgtag	840
tctccagcaa gttccttaac ttctctgcct ccgtttcctt tcctgtaaga tagagtctac	900
ctcagggtta atatgaggat atgcttcttt gctaagtctg gagggcgcta ggaatagcag	960
tggcaggctg tgtcatttct cagtgttgta taacggcttg ttttaaaagt cccactgaaa	1020
actttttttt tttccagatc gaaacacaag tttaatagtc attcagattt cattccagtc	1080
taaagaaact tatagaaatc taattatctg ccagaataac cgcttttaac tgactgtaag	1140
aaccacagtt actttgcagc taaaacagat tgttctcttc ccccaaaca actcggacat	1200
ttagacaaat attgctgctg tctttacatt ttagaaatca gtattaaggc tcacctgtta	1260
ctgaacacat acgagaaaca gttttgttat gcgtatctta tatacatcat gtatacat	1320

tcgtactttc	acatgatgtg	tataataaga	tacacataaa	aactggttgg	cttgtcatga	1380
gtaaattgctt	tattcttttag	agtgaaggaa	tattggatac	agaacgtcgt	tccatattta	1440
atcttgcttt	agaaaattag	gatttatctt	ggacacagca	ttttgaatat	aacacaggca	1500
agttgagtc	tgggggaaaa	attgtatttt	taaattttatt	atcaacggtg	tctttcgc	1560
ttgagaaaac	acatttgaag	atgcccattg	agttccttgg	aagtaaacta	ggtcacccac	1620
cactgaaaca	ccctcggtt	ctgcaaaaag	atgtgcttta	aagagaatag	aatggacgct	1680
cggatatgtt	atctaaacga	ccttgggcaa	gtacgtcgat	tccaaggtac	aatcagccct	1740
cccagacggc	ttttcgagtc	tccctaacc	cgggtgggaga	ggacgcggcg	ccagagccca	1800
gctccggcta	gttttcccgg	gggcaggtgt	agccttgggc	gcggggccgg	gggaggggca	1860
aggggcgggc	gtggggttgg	actgggacgt	gggactcgga	ccacggcctg	ggcgtgggcc	1920
taacgacgcg	ggaccggccc	gccctcgccg	ctccattggc	cacatctgtg	cagaaaaggc	1980
cccgcggccc	aggggcgccc	gcagtgtcac	taggccggct	gggggcccctg	ggtacgctgt	2040
agaccagacc	gcgacaggcc	agaacacggg	cggcggttcc	gggccgggag	acccgcgcag	2100
ccctcggggc	atctcagtc	ctcactcccc	acccctccc	ccgggtcggg	ggaggcggcg	2160
cgtccggcgg	agggttgagg	ggagcggggc	aggcctggag	cgccatgagc	agcccggatg	2220
cgggatacgc	cagtgcagac	cagagccaga	cccagagcgc	gctgcccgcg	gtgatggccg	2280
ggctgggccc	ctgcccctgg	gccgagtcgc	tgagcccat	cggggacatg	aaggtgaagg	2340
gcgaggcgcc	ggcgaacagc	ggagcaccgg	ccggggccgc	gggccgagcc	aagggcgagt	2400
cccgtatccg	gcggccgatg	aacgctttca	tgggtgtggc	taaggacgag	cgcaagcggc	2460
tggcgcagca	gaatccagac	ctgcacaacg	ccgagttgag	caagatgctg	ggtgagtcg	2520
agtcgcagac	ccaggcggcc	gggcgcgctg	gcgcgaatcg	ctaggccgat	ttcttaaacc	2580
ccaaactggt	ctttgcgagc	ctgacgccc	aaaccagggg	tgtgtagcgg	ccacgtcctt	2640
ttttaaggct	ctgggttccc	ttcccgttcc	ccgccctccg	accctccaaa	gcagctttcc	2700
gccttgctct	ccggctccc	gattccccag	gtggccgggg	gcgcgggtcc	aacggctctg	2760
ggaaggcgac	ttcccggcac	ctccgggcgg	cgcgagagca	cccttggccc	tgaactgggc	2820
cggttgtgtc	catccctcga	ccccttccct	agtttaggtgt	ccttttctgt	ttttcgaacg	2880
accgggtgat	gggtgagcgg	aaagccgctt	ccaggagacc	aaaagaaagg	ggtgccttta	2940
gaggacgggt	gttccccaag	ggctcggact	caggagtccc	agatctccct	ctttaacttc	3000
accccggttg	cgcaattcaa	agtctgaggg	gggaggtgcg	tccaggtggg	gccaggtggg	3060
gcctggagcg	ggagcgcagc	cgataagccc	tgcgcccctc	tcccccttcc	ttccactgtg	3120
caggcaagtc	gtggaaggcg	ctgacgctgg	cggagaagcg	gcccttcgtg	gaggaggcag	3180
agcggctgcg	cgtgcagcac	atgcaggacc	acccaacta	caagtaccgg	ccgcggcggc	3240
gcaagcaggt	gaagcggctg	aagcgggtgg	agggcggctt	cctgcacggc	ctggctgagc	3300
cgcaggcggc	cgcgctgggc	cccgaggcg	gccgcgtggc	catggacggc	ctgggcctcc	3360
agttccccga	gcagggcttc	cccgccggcc	cgcgcgtgct	gcctccgcac	atgggcggcc	3420
actaccgcga	ctgccagagt	ctgggcgcgc	ctccgctcga	cggctaccgc	ttgccacgc	3480
ccgacacgtc	cccgtggac					3500

<210> 9

<211> 3500

<212> DNA

<213> Homo sapiens

<400> 9

tgatccctat gactcccctc tgtacaatct ttcctcctgt tctcattgct accttccaat	60
ctcctctttc atttcttcaa ctcttcttcc ttgaaggaac catcccatgt ggcaactcag	120
tttctacctt tccaatgatg attgccagtc ttcactctct cctaaactct aggcttgcat	180
ttctaagtgt tattagggtg tgagcacata tgaccaggt aacgttttga aacgtttgtg	240
cctttcactt ctttcttatt ccattgggtg caatcttgct acttaatact tgaaatgttt	300
ttcaaatttg gatgtttcta gcaatcagct aatgcctttg gcctggttta ggccttcac	360
atctcttgcc tggtttatca aagtcatttt ttaactgaac ttgttgcttt cagttcctct	420
ctgacatgat ggcattaggg taatatttcc atgtgcttca acacacatac cttctcacca	480
ttactatatg tccccccgc cccccccc cagcatcaca ctatctctgg tgtcaccttc	540
tctgttcacg gcctttttct tcttctctag gggttcccc ctttgaagaa acagcatctg	600
ctcaacctcc cctacaggct cccttaaagc tggtttctcc tccctctgtt tgtctctttg	660
caactctctg gaggcattct tacctttaca actttgcatt ttctctgcta ttcccatgta	720
agttccctga aaccctagta ccattcacag caggatttca aaggttgcct gttgcgtgag	780
cattctatag gatcccaa atctttctg tgcaaataatg aattgtttgtg atatgtccgt	840
agagacggca caacctcatg gctaagaatg atagttacca gttctagaga tcctactcta	900
attgtcttag agtggggggc tgaacaccag tattacaaaa aagacaaaag aaaaagaagg	960
aaaaaagaaa aaagaaagag agaaaatcaa agctaccttc atcatgtatg aatttgagca	1020
agtaacacct ttgtgagtc ccaggcccca gtttctcatt ggtaaaatga ggataacaat	1080
tacacagacc ttgttgggct atgtacagaa ttaaatgaga ttatgtacct aaaaggcttg	1140
tggcacagt acacacacac acacacacac acacacacac acaccagag tacttcgtgg	1200
ttatttctag gctttactgc ttgaaaggct gaaaagatgg gtggatgaga ggtgcctga	1260
ggttccctcc aactctcaa gattctgtga tactcctcct tgggtgctga agacactttg	1320
gcaatgtttg gatttccaaa cggttgctta gaaaactaag ggaccacga agcccaggta	1380
agcctcaggg tctttcccag gaatcgttta tttatttgat cttagttctg acctagagcc	1440
tccaccttct ccatccaat caccacagt gtcgaaaagg gcctgtgctt gggaaatcct	1500
tcctttgttg gcgaatcttg gaccctaac ctgcattttg gcctctgaca ccataggcc	1560
catggttcaa acccaggcgg ctctttccaa gttcgaagca gggactcggg tctgcgcatc	1620
tggcggtgt gccagattg taaccttcgc actaggcatc caagaacgtg ctttgacac	1680
actcggcggg gggagcgggt gcttggtttg catcagggat gaggggtgga gtagcgaaag	1740
cgcgcggagc gcgcactcac tcacactccc caagccaggg cgcggccgct ctgggcgcga	1800
ggtcccaagc caagtctgc gctcggccag gagccgggga gtacccagg tccccggtct	1860
ggggccgccc ctatcctacc ctgcggcgcg cactcctgac ctggccccgc cccccggcg	1920
ccgcgagtag cgggcggagc gcaagcagag aggcgctctg ggctgtgcgg caccgcctct	1980

cctcgggtgtc tggggaggga cggaggggacc gggcgggaga gagagaaagc ctgaccgacc 2040
 ggctggcgaa gagctgcatg caaccgggtgg gaggccgggc cggctgggtc tggggctcgg 2100
 gctcaggctc gcaccgtttc tcggcaggtc cctggcgggtg agcgcggacg gcccggaggc 2160
 ggcggctctg agctggcagg cggagggtg tctcctgcgc ccgcctgccc ggcgcgggtcc 2220
 gaggatgcgg gggggcgatg cccggggcca gggacgcgct ctgtcaccag gcgctgcagc 2280
 tgctggccga gctctgtgcc cgtggggccc tggagcacga cagctgccag gatttcattt 2340
 accacctgcg ggaccgtgcc agaccccggc tccgcgaccc aggtgagtgc cgccaccgcc 2400
 gcctggaggg acctaagggc cctgggctgg gacttggggc cgcaccgggg cctgaggcag 2460
 aacagcgacg cggactggga gagggcgggg ggcggccacc gagccaggag agtgatcaag 2520
 aaccagcgca ctgtggcctg atgtgtaac caggcgggga cccgggcggt ggctactgca 2580
 cggaggccga ctccgggtcg gctagggcag ggttggaggg accacgcccg ccacctgcgc 2640
 tcccatcgcc aaggctcctg ggggcggctc cctagctccg agctacgctc tccacttccc 2700
 gggctatctg cactcagagc gaggggaggc cgcggcggcc tcggagccgt gggaaggggg 2760
 acgaggccga aggaaactct gggaagttag gagttgggga cggccccggg ttggggccga 2820
 atcccaccgg gtgctgctca tcctttctcc caagcgtcta gttcctttcc ttggtatggg 2880
 gtgagaaggg cgggacgca tccggcggtg ggccggggac aggggtgcttc tggccttggg 2940
 cagacgggcc tgaaccggtt cccggcgggt cgcacggcat ggaggtggcc tgggcctggg 3000
 cgctaggctc gaccagcgac taccgccggc cacgatgggg ttcgtagact cgtcggctct 3060
 ggcttgtgca cctgtagtta ctctagtga aagttgcaa gctcttaact ttggaaagtt 3120
 catttatattt ggcatattgac caattaaggt tggaggaggg agtttttagtg gagccatttg 3180
 cttttcctga ggtccctggg tctcccagggt cgtctcatcc gttactggct actggaaaat 3240
 gcatccttc caatgtttgc ttgagatgtt tctcacctgg agaaatagtt ttctcgaata 3300
 ttctcccaac ctaagtactt accaaaacag catattgtgg ttggattgtt aaaaatggga 3360
 tgagaaaatg gcctttctct tgatattgct atgtataaat attggaaatg agctattgcc 3420
 ttgcaaatta tgatgtacga attgaaaaca atttattata taaaaatcca tttatccaaa 3480
 agataaatta aagaattatt 3500

<210> 10

<211> 28

<212> DNA

<213> artificial sequence

<400> 10

ggttaggtag tttcgttttc ggatagtc

28

<210> 11

<211> 24

<212> DNA

<213> artificial sequence

<400> 11

aaacacaaa acgaacgacc gaca

24

<210> 12

<211> 27

<212> DNA

<213> artificial sequence

<400> 12

tttggtagag tttttcgatt cggtagc

27

<210> 13

<211> 21

<212> DNA

<213> artificial sequence

<400> 13

accgaaactc cgcgccgata a

21

<210> 14

<211> 25

<212> DNA

<213> artificial sequence

<400> 14

gtaagagttt gggagcgttc gagtc

25

<210> 15

<211> 23

<212> DNA

<213> artificial sequence

<400> 15

caaaaaatcc cgaaaacaac gac

23

<210> 16
<211> 27
<212> DNA
<213> artificial sequence
<400> 16
cgtagagttc gagatgtggt attaggc 27

<210> 17
<211> 27
<212> DNA
<213> artificial sequence
<400> 17
aaactcctat acgaaaaaaaa cgcgcta 27

<210> 18
<211> 26
<212> DNA
<213> artificial sequence
<400> 18
tactccccctc aaacttaaatt cctttc 26

<210> 19
<211> 16
<212> DNA
<213> artificial sequence
<400> 19
gcgggacggtt gcgaag 16

<210> 20
<211> 19
<212> DNA
<213> artificial sequence

<400> 20	
agcgcgggcg ttgagtagc	19
<210> 21	
<211> 26	
<212> DNA	
<213> artificial sequence	
<400> 21	
cgcgctccta acaaaataac aacgaa	26
<210> 22	
<211> 25	
<212> DNA	
<213> artificial sequence	
<400> 22	
ttgtttcgcg ttttttaatg ttagc	25
<210> 23	
<211> 25	
<212> DNA	
<213> artificial sequence	
<400> 23	
aaaaaaactc cgaaaacgac gaaat	25
<210> 24	
<211> 20	
<212> DNA	
<213> artificial sequence	
<400> 24	
ggagattcgc gtagttttcg	20
<210> 25	
<211> 18	

<212> DNA	
<213> artificial sequence	
<400> 25	
aacccgacca tcaccgcg	18
<210> 26	
<211> 25	
<212> DNA	
<213> artificial sequence	
<400> 26	
tggggtcgtc gttatatttat tttgc	25
<210> 27	
<211> 18	
<212> DNA	
<213> artificial sequence	
<400> 27	
ccgcccgatc cctccgtc	18